Clinical Trials on Alzheimer's Disease

November 14-16, 2013
San Diego

www.ctad-alzheimer.com
Dear Colleague,

We are proud to present our program for the 6th annual conference Clinical Trials for Alzheimer’s Disease CtaD 2013 in San Diego, CA – USA on November 14-16, 2013.

This year the CtaD conference will relate experiences from international teams covering every stage of clinical trials in AD. From animal models to human trials, CtaD 2013 provides an opportunity to learn about the latest results in drug trials as well as important topics such as internet screening of cognition to recruit for clinical trials, designing drug trials taking into account neuropsychiatric symptoms of AD, Down syndrome and AD as well as ethical issues and methodological considerations.

Again this year CTAD is the perfect opportunity to exchange views with your peers on the difficulties and challenges of Alzheimer’s disease and take home some hands-on therapeutic and methodological tools to improve and reinforce your AD research and clinical trial teams. UC San Diego School of Medicine reviewed and awarded CtaD 2013 with 18 AMA PRA Category 1 Credits™ in compliance with ACCME essentials and Standards and CME policies and procedures.

We are very happy to welcome you to CTAD 2013!

SCIENTIFIC COMMITTEE
Susan ABUSHAKRA (San Francisco)  
Paul AISEN (San Diego)  
Kaj BLENNOW (Molndal)  
Merce BOADA (Barcelona)  
Robert BRASHEAR (San Francisco)  
Maria CARRILLO (Chicago)  
Mony John DE LEON (New York)  
Rachelle DOODY (Houston)  
Bruno DUBOIS (Paris)  
Howard FELDMAN (Vancouver)  
Nick FOX (London)  
Giovanni B. FRISONI (Brescia)  
Lutz FROELICH (Mannheim)  
Serge GAUTHIER (Montreal)  
Ezio GIACOBINI (Geneva)  
Michael GRUNDMANN (San Diego)  
Harald HAMPEL (Munich)  
Takeshi IWATSUBO (Tokyo)  
Zaven KHACHATURIAN (Washington DC)  
Virginia LEE (Philadelphia)  
Jean-Marc ORGOGOZO (Bordeaux)  
Ronald PETERSEN (Minnesota)  
Stephen SALLOWAY (Providence)  
Philip SCHELTENS (Amsterdam)  
Lon SCHNEIDER (Los Angeles)  
Eric SIEMERS (Philadelphia)  
Peter SNYDER (Rhode Island)  
Reisa SPERLING (Boston)  
Yaakov STERN (New York)  
Jacques TOUCHON (Montpellier)  
John TROJANOWSKI (Philadelphia)  
Bruno VELLAS (Toulouse)  
Michael W. WEINER (San Francisco)  
Gordon WILCOCK (Oxford)  
Bengt WINBLAD (Stockholm)

ORGANIZING COMMITTEE
Paul AISEN  
Jacques TOUCHON  
Bruno VELLAS  
Michael WEINER

CONGRESS SECRETARIAT
ANT Congrès  
E-mail : ctad@ant-congres.com  
Ph : + 33 4 67 10 92 23
Keynote speakers

Paul S. Aisen M.D. is the Director of the Alzheimer’s Disease Cooperative Study (ADCS) and Professor in the Department of Neurosciences at UCSD. He has been conducting therapeutic research on Alzheimer’s disease for the past two decades. Dr. Aisen joined the faculty at Georgetown University in 1999 as Professor in the Departments of Neurology and Medicine and that year, he founded the Memory Disorders Program, a clinical and research program for Alzheimer’s disease and related disorders. He continued basic research studies on therapeutic targets and biomarkers of AD and designed and directed multicenter therapeutic trials. He became Vice Chair of the Department of Neurology at Georgetown in 2004. Following the tragic death of ADCS founder Leon Thal, M.D. in early 2007, Dr. Aisen relocated to UCSD to assume the position of Director of the ADCS and Professor of Neurosciences.

Jeffrey Cummings, MD, ScD, is Director of Cleveland Clinic Lou Ruvo Center for Brain Health and the Camille and Larry Ruvo Chair for Brain Health. Dr. Cummings’ research and leadership in the field of Alzheimer’s disease have been recognized with many awards, including the Henderson Award of the American Geriatrics Society, the Research Award of the John Douglas French Alzheimer’s Research Foundation, and the Ronald and Nancy Reagan Research Award of the national Alzheimer’s Association.

Dr. Cummings is the author of the Neuropsychiatric Inventory (NPI), the most commonly used tool for characterizing behavioral disturbances in dementia syndromes and for measuring the effect of therapies on neuropsychiatric symptoms in Alzheimer’s disease and other dementias.

Serge Gauthier, MD, FRCPC - Dr. Gauthier is currently Professor in the Departments of Neurology & Neurosurgery, Psychiatry, Medicine, at McGill University, and Director of the Alzheimer Disease and Related Disorders Research Unit of the McGill Center for Studies in Aging, Douglas Hospital.

He did his medical training at Université de Montréal, Neurology training at McGill University, Research Fellowship at Prof. Theodore L. Sourkes laboratory, Allen Memorial Institute, Montreal. Clinical investigator and staff neurologist at the Montreal Neurological Hospital and Institute (1976-1986), Director of the McGill Centre for Studies in Aging (1886-1996), Senior Scientist of the CIHR-Rx&D program (1997-2007).

Contributions to research include design and implementation of randomized clinical trials in order to establish the safety and efficacy of cholinesterase inhibitors, muscarinic agonists, and agents possibly modifying progression for Alzheimer’s disease and vascular dementia. Special interests include consensus approach to the management of dementia in different stages, the ethics of research involving persons with dementia, and primary prevention strategies against cognitive decline and dementia.

David M. Holtzman, is the Andrew B. and Gretchen P. Jones Professor and Chairman of Neurology, Professor of Developmental Biology, Associate Director of the Alzheimer’s Disease Research Center, and a member of the Hope Center for Neurological Disorders at the Washington University School of Medicine in St. Louis, MO – USA

His major interest is in understanding basic mechanisms underlying acute and chronic cell dysfunction in the CNS particularly as these mechanisms may relate to Alzheimer’s disease (AD) and injury to the developing brain.
Keynote speakers

**William C. Mobley** is a Distinguished Professor and Chair of the Department of Neurosciences at UCSD. He also serves as Executive Director of UCSD’s Down Syndrome Center for Research and Treatment. Dr. Mobley has a distinguished record of academic achievement and is considered one of the most outstanding academic neurologists in the US. He has an international reputation for his research on degenerative disease of the central nervous system as well as being a leader in translational medicine, bridging clinical and basic science in various areas. More

**Ronald C. Petersen, MD, PhD** is the Director of the Mayo Alzheimer’s Disease Research Center and has an interest in clinical research involving aging, mild cognitive impairment, dementia, Alzheimer’s Disease, and neuroimaging. The Mayo Alzheimer’s Disease Research Center is part of a network of 28 centers around the country sponsored by the National Institute on Aging. This center operates in Rochester, MN and Jacksonville, FL. In addition, Dr. Petersen has a National Institute on Aging funded registry on aging and dementia in Rochester. This is a longitudinal project on clinical, epidemiological, genetic, biomarker, imaging, and neuropathological aspects of aging and very early cognitive impairment. His team is developing models for predicting a subsequent cognitive impairment in normal elderly persons. A great deal of his work has focused on mild cognitive impairment as an intermediate stage between normal aging and Alzheimer’s disease. Recently, he has begun a project funded by the Mayo Foundation investigating various aspects of successful cognitive aging in the community. He also studies non-Alzheimer’s disease dementias such as frontotemporal dementia, dementia with Lewy bodies and vascular dementia.

**Dr. Eric Reiman** is chief executive officer of Banner Research, executive director of Banner Alzheimer’s Institute, clinical director of the Neurogenomics Division at the Translational Genomics Research Institute (TGen), professor of psychiatry at the University of Arizona, and director of the Arizona Alzheimer’s Consortium. His research interests include brain imaging, genomics and their application to the study of normal and abnormal human behaviors; the early detection, tracking and study of Alzheimer’s disease; and the accelerated evaluation of presymptomatic Alzheimer’s disease treatments. Dr. Reiman is internationally recognized for his contributions to the fields of brain imaging, the behavioral neurosciences and the presymptomatic study of Alzheimer’s disease.
Contents

CTAD 2013 Program ................................................................. p. 4 - 17

Program at a glance ................................................................. p. 4 - 5

Thursday, November 14th .......................................................... p. 6 - 10

Friday, November 15th ............................................................... p. 11 - 15

Saturday, November 16th .......................................................... p. 16 - 17

Poster presentations ................................................................. p. 18 - 28

General information ................................................................. p. 29

Continuing Medical Education .................................................. p. 30 - 31

Faculty List .............................................................................. p. 32 - 33

Disclosure summary ................................................................. p. 34 - 38

Acknowledgements .................................................................. p. 38
# Program at a glance

## Thursday, November 14th

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 8.00 - 8.15 a.m | WELCOME BY THE ORGANIZING COMMITTEE  
California Ballroom ABC |
| 8.15 - 8.45 a.m | OPENING KEYNOTE  
Toward effective Alzheimer’s therapy : progress and collaboration  
California Ballroom ABC |
| 8.45 - 10.00 a.m | Symposium 1  
Clinical trials in early stage Alzheimer’s disease: Current methodological and regulatory considerations  
California Ballroom ABC |
| 10.00 - 10.30 a.m | KEYNOTE  
When to Treat: Biomarkers in MCI and Pre-Clinical AD  
California Ballroom ABC |
| 11.00 - 12.45 p.m | PARALLEL SESSIONS: ORAL COMMUNICATIONS  
**DATA FROM CLINICAL TRIALS**  
California Ballroom AB  
**IMAGING IN CLINICAL TRIALS ON AD**  
California Ballroom C  
Lunch Break and poster sessions - San Diego Ballroom |
| 1.45 - 3.00 p.m | PARALLEL SESSIONS: ORAL COMMUNICATIONS  
**STUDY DESIGN FOR CLINICAL TRIALS**  
California Ballroom AB  
**PRECLINICAL STUDIES IN ALZHEIMER’S DISEASE**  
California Ballroom C |
| 3.00 - 3.45 p.m | PARALLEL SESSIONS: ORAL COMMUNICATIONS  
**COGNITIVE AND IMAGING ASSESSMENT FOR CLINICAL TRIALS**  
California Ballroom AB  
**PET IMAGING OF TAU PATHOLOGY**  
California Ballroom C  
Coffee Break and poster sessions - San Diego Ballroom |
| 4.15 - 4.45 p.m | KEYNOTE  
The New Era in Alzheimer’s Prevention Research  
California Ballroom ABC |
| 4.45 - 6.00 p.m | Symposium 2  
Rethinking the Way to Conduct Drug Trials in Alzheimer ’s disease  
California Ballroom ABC |
| 6.30 p.m | Bus departure to the Welcome Reception  
Lobby of the Westin Gaslamp Quarter |
| 7.00 p.m | Welcome Reception at the Omni Hotel |
**Friday, November 15th**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>8.30 - 9.00 a.m</td>
<td><strong>KEYNOTE</strong></td>
</tr>
<tr>
<td></td>
<td>AD and Down’s syndrome</td>
</tr>
<tr>
<td></td>
<td><strong>California Ballroom ABC</strong></td>
</tr>
<tr>
<td>9.00 - 10.15 a.m</td>
<td><strong>Symposium 3</strong></td>
</tr>
<tr>
<td></td>
<td>Agitation and Aggression in AD: A New Target for Drug Development</td>
</tr>
<tr>
<td></td>
<td><strong>California Ballroom ABC</strong></td>
</tr>
<tr>
<td>10.45 - 12.15 p.m</td>
<td><strong>PARALLEL SESSIONS: ORAL COMMUNICATIONS</strong></td>
</tr>
<tr>
<td></td>
<td>COMPOSITE OUTCOMES FOR CLINICAL TRIALS</td>
</tr>
<tr>
<td></td>
<td>NEUROIMAGING PET FOR CLINICAL TRIALS</td>
</tr>
<tr>
<td></td>
<td><strong>California Ballroom AB</strong></td>
</tr>
<tr>
<td></td>
<td><strong>California Ballroom C</strong></td>
</tr>
<tr>
<td>11.00 - 12.00 a.m</td>
<td><strong>Coffee Break and poster sessions</strong> - San Diego Ballroom</td>
</tr>
<tr>
<td>1.15 - 3.15 p.m</td>
<td><strong>PARALLEL SESSIONS: ORAL COMMUNICATIONS</strong></td>
</tr>
<tr>
<td></td>
<td>TREATMENT ASSESSMENT FOR CLINICAL TRIALS</td>
</tr>
<tr>
<td></td>
<td>BIOMARKERS FOR CLINICAL TRIALS</td>
</tr>
<tr>
<td></td>
<td><strong>California Ballroom AB</strong></td>
</tr>
<tr>
<td></td>
<td><strong>California Ballroom C</strong></td>
</tr>
<tr>
<td>3.45 - 4.15 p.m</td>
<td><strong>KEYNOTE</strong></td>
</tr>
<tr>
<td></td>
<td>Designing drug trials taking into account neuropsychiatric symptoms of AD</td>
</tr>
<tr>
<td></td>
<td><strong>California Ballroom ABC</strong></td>
</tr>
<tr>
<td>4.15 - 5.30 p.m</td>
<td><strong>Symposium 4</strong></td>
</tr>
<tr>
<td></td>
<td>Internet screening of cognition as a method for recruiting to clinical trials in prodromal Alzheimer’s disease</td>
</tr>
<tr>
<td></td>
<td><strong>California Ballroom ABC</strong></td>
</tr>
<tr>
<td>5.30 - 6.00 p.m</td>
<td><strong>KEYNOTE</strong></td>
</tr>
<tr>
<td></td>
<td>Ethical issues in AD prevention trials: genetics, biomarkers and treatment risk</td>
</tr>
<tr>
<td></td>
<td><strong>California Ballroom ABC</strong></td>
</tr>
</tbody>
</table>

**Saturday, November 16th**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>8.00 - 8.30 a.m</td>
<td><strong>KEYNOTE</strong></td>
</tr>
<tr>
<td></td>
<td>Novel immunotherapy approaches</td>
</tr>
<tr>
<td></td>
<td><strong>California Ballroom AB</strong></td>
</tr>
<tr>
<td>8.30 - 10.00 a.m</td>
<td><strong>PARALLEL SESSIONS</strong></td>
</tr>
<tr>
<td></td>
<td>ORAL COMMUNICATIONS</td>
</tr>
<tr>
<td></td>
<td>8.30 - 9.00 a.m</td>
</tr>
<tr>
<td></td>
<td>BIOMARKERS FOR CLINICAL TRIALS</td>
</tr>
<tr>
<td></td>
<td><strong>California Ballroom C</strong></td>
</tr>
<tr>
<td></td>
<td>9.00 - 10.00 a.m</td>
</tr>
<tr>
<td></td>
<td>PRECLINICAL STUDIES IN AD</td>
</tr>
<tr>
<td></td>
<td><strong>California Ballroom C</strong></td>
</tr>
<tr>
<td>10.30 - 11.45 a.m</td>
<td><strong>Symposium 6</strong></td>
</tr>
<tr>
<td></td>
<td>CSF biomarkers in clinical trials</td>
</tr>
<tr>
<td></td>
<td><strong>California Ballroom AB</strong></td>
</tr>
</tbody>
</table>
# CTAD 2013 Program

**Thursday, November 14th**

<table>
<thead>
<tr>
<th>Time</th>
<th>Location</th>
<th>Event Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>8.00 a.m</td>
<td>California Ballroom ABC</td>
<td><strong>Welcome by the organizing committee and presentation of the CtaD Lifetime Achievement Award in Alzheimer’s Disease Therapeutic Research</strong>, to Russell Katz MD, former Director, Division of Neurology Products, U.S. Food and Drug Administration. Paul Aisen, Jacques Touchon, Bruno Vellas, Mike Weiner.</td>
</tr>
<tr>
<td>8.15 a.m</td>
<td><strong>OPENING KEYNOTE</strong> - California Ballroom ABC</td>
<td>Toward effective Alzheimer’s therapy: progress and collaboration. Paul Aisen, MD, University of California at San Diego, USA.</td>
</tr>
<tr>
<td>8.45 a.m</td>
<td><strong>SYMPOSIUM 1</strong> - California Ballroom ABC</td>
<td>Clinical trials in early stage Alzheimer’s disease: Current methodological and regulatory considerations. Moderators: John Harrison PhD, Metis Cognition Ltd, Kilmington Common, Wiltshire, UK.</td>
</tr>
<tr>
<td>8.45 a.m</td>
<td>California Ballroom ABC</td>
<td>1. What are we trying to measure in preclinical and prodromal Alzheimer’s disease? Lon Schneider MD, MS. Keck School of Medicine of the University of Southern California, USA.</td>
</tr>
<tr>
<td>8.45 a.m</td>
<td>California Ballroom ABC</td>
<td>2. How can changes in cognitive function be measured in therapeutic trials in preclinical AD? Keith Wesnes PhD, Bracket Global, Goring UK &amp; Swinburne University, Melbourne, Australia.</td>
</tr>
<tr>
<td>8.45 a.m</td>
<td>California Ballroom ABC</td>
<td>3. A regulatory perspective on therapeutic trials in early stage Alzheimer’s disease. Nicholas Kozauer MD, Food and Drug Administration, Silver Spring, MD, USA.</td>
</tr>
<tr>
<td>10.00 a.m</td>
<td><strong>KEYNOTE</strong> - California Ballroom ABC</td>
<td>When to treat: Biomarkers in MCI and pre-clinical AD. Ronald C. Petersen, M.D., Ph.D., Mayo Alzheimer’s Disease Research Center, Mayo Clinic, Rochester, MN, USA.</td>
</tr>
<tr>
<td>10.30 a.m</td>
<td><strong>Coffee Break and poster sessions</strong> - San Diego Ballroom</td>
<td></td>
</tr>
<tr>
<td>11.00 a.m</td>
<td><strong>PARALLEL SESSIONS: ORAL COMMUNICATIONS</strong></td>
<td></td>
</tr>
<tr>
<td>11.00 a.m</td>
<td>California Ballroom AB</td>
<td><strong>DATA FROM CLINICAL TRIALS</strong> - Stereotactic gene delivery of NGF (via AAV2-NGF) in AD patients: Safe &amp; effective targeting to degenerating cholinergic neurons. Raymond T. Bartus, PhD (1,2), Tiffany L. Baumann, BS (1,3), Roy A.E. Bakay, MD (4), Jeffrey M. Ostrove, PhD (1), Joao Siffert, MD (1,5), Adam S. Fleisher, MD (6,7), Christopher D. Herzog, PhD (1), David Barba, MD (6), Mary Pay, APN (6), David P. Salmon, MD (6), Yaping Chu, MD (4), Jeffrey H. Kordower, PhD (4), Kathie Bishop, PhD (1,3), David Keator, PhD (8), Steven Potkin, MD (8), Michael S. Rafii, MD (6).</td>
</tr>
<tr>
<td>11.00 a.m</td>
<td>California Ballroom C</td>
<td><strong>IMAGING IN CLINICAL TRIALS ON AD</strong> - Improvements to attention and verbal episodic memory with memantine in Parkinson’s disease dementia and dementia with Lewy bodies. Keith A. Wesnes (1,2,3), Clive Ballard (5), Elisabet Londos (6).</td>
</tr>
<tr>
<td>11.00 a.m</td>
<td>California Ballroom AB</td>
<td><strong>DATA FROM CLINICAL TRIALS</strong> - Baseline memory problems associate with clinical impairments eight years later: centralized follow-up in the PREADVISE trial. Richard Kryscio, PhD (1,2), Erin Abner, PhD (2), Allison Caban-Holt, PhD (2,3), Melissa Mathews, PhD (4), Frederick Schmitt, PhD (2,3,4,5).</td>
</tr>
<tr>
<td>11.00 a.m</td>
<td>California Ballroom AB</td>
<td><strong>IMAGING IN CLINICAL TRIALS ON AD</strong> - When to treat: Biomarkers in MCI and pre-clinical AD. Ronald C. Petersen, M.D., Ph.D., Mayo Alzheimer’s Disease Research Center, Mayo Clinic, Rochester, MN, USA.</td>
</tr>
</tbody>
</table>

---

**4th November 2013**

**Program**

**Opening Session**

- **Welcome & Introduction** by the organizing committee and presentation of the CTA Lifetime Achievement Award in Alzheimer’s Disease Therapeutic Research, to Russell Katz MD, former Director, Division of Neurology Products, U.S. Food and Drug Administration.

**Symposium 1**

- Clinical trials in early stage Alzheimer’s disease: Current methodological and regulatory considerations.
  - Question 1: What are we trying to measure in preclinical and prodromal Alzheimer’s disease?
    - Lon Schneider MD, MS, Keck School of Medicine of the University of Southern California, USA.
  - Question 2: How can changes in cognitive function be measured in therapeutic trials in preclinical AD?
    - Keith Wesnes PhD, Bracket Global, Goring UK & Swinburne University, Melbourne, Australia.
  - Question 3: A regulatory perspective on therapeutic trials in early stage Alzheimer’s disease.
    - Nicholas Kozauer MD, Food and Drug Administration, Silver Spring, MD, USA.

**Keynote**

- When to treat: Biomarkers in MCI and pre-clinical AD.
  - Ronald C. Petersen, M.D., Ph.D., Mayo Alzheimer’s Disease Research Center, Mayo Clinic, Rochester, MN, USA.

**Coffee Break**

**Parallel Sessions**

1. **OC1** - Stereotactic gene delivery of NGF (via AAV2-NGF) in AD patients: Safe & effective targeting to degenerating cholinergic neurons.
   - Raymond T. Bartus, PhD (1,2), Tiffany L. Baumann, BS (1,3), Roy A.E. Bakay, MD (4), Jeffrey M. Ostrove, PhD (1), Joao Siffert, MD (1,5), Adam S. Fleisher, MD (6,7), Christopher D. Herzog, PhD (1), David Barba, MD (6), Mary Pay, APN (6), David P. Salmon, MD (6), Yaping Chu, MD (4), Jeffrey H. Kordower, PhD (4), Kathie Bishop, PhD (1,3), David Keator, PhD (8), Steven Potkin, MD (8), Michael S. Rafii, MD (6).

2. **OC2** - Improvements to attention and verbal episodic memory with memantine in Parkinson’s disease dementia and dementia with Lewy bodies.
   - Keith A. Wesnes (1,2,3), Clive Ballard (5), Elisabet Londos (6).

3. **OC3** - Baseline memory problems associate with clinical impairments eight years later: centralized follow-up in the PREADVISE trial.
   - Richard Kryscio, PhD (1,2), Erin Abner, PhD (2), Allison Caban-Holt, PhD (2,3), Melissa Mathews, PhD (4), Frederick Schmitt, PhD (2,3,4,5).
DATA FROM CLINICAL TRIALS - California Ballroom AB

11.45 a.m  
**OC4** - Bayesian longitudinal modeling on placebo data from Alzheimer’s disease clinical studies  
Yun-Fei Chen (1), Richard Mohs (1), Ying Ding (2), Paul Aisen (3), Ronald G. Thomas (3)  
(1) Eli Lilly and Company, USA, (2) University of Pittsburgh, USA, (3) University of California, San Diego, USA

12.00 p.m  
**OC5** - Mild versus moderate stage of Alzheimer’s disease three-year outcomes of cholinesterase inhibitor therapy in a routine clinical setting  
Carina Wattmo, RN, BSc, PhD, Lennart Minthon, MD, PhD, Åsa K. Wallin, MD, PhD  
Clinical Memory Research Unit, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden

12.15 p.m  
**OC6** - The NIA ASPREE trial–aspirin in reducing events in the elderly  
Anne M. Murray, MD (1), Richard H Grimm, MD, PhD (2), Brenda Kirpach (2), John McNeil, MD, PhD (3), Robyn Woods, PhD, (3), Mark Nelson, MD, PhD (3), Elsdon Storey, MD (3), A.Tonkin, MD (3), Raj Shah, MD (4)  
(1) Department of Medicine and Geriatrics, Hennepin County Medical Center, Minneapolis, MN USA, (2) Berman Center for Clinical Trials, Minneapolis Medical Research Foundation and University of Minnesota, Minneapolis, MN, USA, (3) Monash University, Department of Epidemiology & Preventive Medicine, Melbourne, Australia, T.Lockett, Preventative Health National Research Flagship, Commonwealth Scientific and Industrial Research Organisation (CSIRO) Molecular and Health Technologies, North Ryde, NSW, Australia, (4) Rush Alzheimer’s disease center, Chicago, IL, USA

12.30 p.m  
**OC7** - A first-in-human study of BAN2401, a novel monoclonal antibody against amyloid-β protofibrils  
Veronika Logovinsky, MD, PhD (1), Robert Lai, MA, MB BChir, PhD, MRCP, FFPM (2), Kenan Gu, PhD (3), Yanke Yu, PhD (3), Chad J. Swanson, PhD (1), Andrew Satlin, MD (1)  
(1) Eisai Inc. Woodcliff Lake, NJ, USA, (2) Eisai Ltd. London, UK, (3) Eisai Inc. Andover, MA, USA

IMAGING IN CLINICAL TRIALS ON AD - California Ballroom C

Moderators: Mark Mintun, Joyce Suhy

11.15 a.m  
**OC8** - Increasing role of imaging in Alzheimer disease trials: issues and risk management strategies  
Kohkan Shamsi MD, PhD  
Founder and Principal, RadMD, New York, NY, USA

11.30 a.m  
**OC9** - Performance metrics for two large phase III Alzheimer’s disease clinical trials; an MRI perspective  
Rahul Peethala, Joyce Suhy, Joonmi Oh  
Synarc Inc, Newark, NJ, USA

11.45 a.m  
**OC10** - Effects of ELND005 (Scylloinositol) long term treatment on Amyloid related imaging abnormalities (ARIA) in Phase 2 AD studies  
Anton P. Porsteinsson (1), Christopher VanDyck (2), Matthias Kurth (3), Sheila O’Mahony (3), Aartl Verma (3), Gerald Crans (3), J. Patrick Kesslak (3), Susan Abushakra (3)  
(1) Department of Psychiatry, University of Rochester, (2) Department of Neurology, Yale University, (3) Elan Pharmaceuticals, Inc., Global Development, San Francisco CA

12.00 p.m  
**OC11** - MRI findings in patients on placebo in phase 3 clinical trials of mild-moderate Alzheimer’s disease  
Janssen Alzheimer Immunotherapy R&D, LLC, South San Francisco, CA - USA

12.15 p.m  
**OC12** - Preliminary analysis of baseline FDG PET in PET substudies of Phase 3 i.v. bapineuzumab trials in mild to moderate AD: Patterns and severity of regional brain hypometabolism and relationship to fibrillary amyloid burden measured by 11C-PiB PET and clinical outcomes  
Schmidt ME, MD (1), Gregg K, PhD (1), Margolin R, MD (1), Lukic AS, PhD (2), Andrews RS, MS (2), Matthews DC, MS, MBA (2), Wernick MN, PhD (2), Strother SC, PhD (2), Brashear R, MD (1), Liu E, PhD (1)  
(1) Janssen Alzheimer Immunotherapy R&D, LLC, South San Francisco, CA, USA, (2) ADMx, Chicago, IL, USA

12.30 p.m  
**OC13** - Longitudinal LEAP is equivalent to semi-automatic VBSI on ADNI data in terms of group separation  
Katherine R. Gray, PhD (1,2), Robin Wolz, PhD (1,2), Mark Austin, PhD (1), Daniel Rueckert, PhD (2), Kate McLeish, PhD (1), Derek Hill, PhD (1)  
(1) IXICO Ltd, London, United Kingdom, (2) Department of Computing, Imperial College London, United Kingdom

12.45 p.m  
**Lunch Break and poster sessions** - San Diego Ballroom
CTAD San Diego 2013 Program

Thursday, November 14th

1.45 - 3.00 p.m PARALLEL SESSIONS: ORAL COMMUNICATIONS

STUDY DESIGN FOR CLINICAL TRIALS - California Ballroom AB
Moderators: Susan Abushakra, Lon Schneider

1.45 p.m  
**OC14** - A pharmacogenetics supported clinical trial to delay onset of mild cognitive impairment due to Alzheimer’s disease: An update  
Allen D. Roses, MD (1,2), Kathleen A. Welsh-Bohmer, PhD (2), Daniel K. Burns, PhD (1), Carl Chiang, PhD (1), Donna G. Crenshaw, PhD (1,2), Michael W. Lutz, PhD (1,2), Craig A. Metz, PhD (1), Ann M. Saunders, PhD (1,2), Deborah Yarbrough, MS, MBA (3), Stephen Brannan, MD (3), Kumar Budur, MD, MS (3)  
(1) Zinfandel Pharmaceuticals, Inc., Durham, NC, USA, (2) Duke Bryan ADRC, Durham, NC, USA, (3) Takeda Global Research & Development Center, Inc., Deerfield, IL, USA

2.00 p.m  
**OC15** - Evidence that compromised neurogenesis in Alzheimer’s disease is linked to APOE ε4 status and CSF Aβ42  
Keith A. Wesnes PhD (1,2), Peter Annas PhD (3), Hans Basun MD PhD (4), Kaj Blennow MD PhD (5)  
(1) Bracket Global, Goring on Thames, UK, (2) Centre for Human Psychopharmacology, Swinburne University, Melbourne, Australia, (3) Astra Zeneca, R&D Södertälje, Sweden, (4) BioArctic Neuroscience AB, Sweden, (5) Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden

2.15 p.m  
**OC16** - Imputation of amyloid status in a mild AD clinical trial cohort using a structural MRI based shape variation signature  
Duygu Tosun, PhD (1), Peng Yu, PhD (2), Peter Castelluccio, MS (2), Yun-Fei Chen, PhD (2), Joyce Suhy, PhD (2), Eric R Siemers, MD (2), Adam J Schwarz, PhD (2), Michael Weiner, MD (1)  
(1) Department of Radiology and Biomedical Imaging, University of California San Francisco, CA, USA, (2) Eli Lilly and Company, Indianapolis, IN, USA, (3) SynarcInc, San Francisco, CA, USA

2.30 p.m  
**OC17** - Anti-amyloid therapies: influence of ApoE genotypes and CSF Aβ levels on inclusion of patients  
Julien Dumurgier MD PhD (1), Jean Louis Laplanche PharmD PhD (2), Jacques Hugon MD PhD (1), Claire Paquet MD PhD (1)  
(1) Memory Center Lariboisiere Hospital Paris France, (2) Department of Biochemistry Lariboisiere Hospital Paris, France

2.45 p.m  
**OC18** - A better way to measure the progress of pre-symptomatic AD?  
John Breitner, MD, MPH  
McGill University Faculty of Medicine, Centre for Studies on Prevention of AD Investigators, Montreal, Québec, Canada

PRECLINICAL STUDIES IN ALZHEIMER’S DISEASE - California Ballroom C
Moderators: David Holtzman, Zaven Kachaturian

1.45 p.m  
**OC19** - New cellular models for drug discovery in Alzheimer’s disease  
Jordan L. Holtzman, M.D., Ph.D. (1,2,3)  
(1) Departments of Pharmacology, (2) Medicine, and (3) Division of Environmental Health Sciences, University of Minnesota, Minneapolis, MN, USA

2.00 p.m  
**OC20** - Brain structural connectivity in two mouse models of Alzheimer’s disease: an in vivo diffusion study  
Moira Marizzoni, PhD (1), Edoardo Micotti, PhD (2), Alessandra Paladini, MS (2), Claudia Balducci, PhD (2), Anna Caroli, PhD (1,3), Sophie Dix, PhD (4), Christian Czech, PhD (5), Laurence Ozmen, PhD (5), Jill C. Richardson, PhD (6), Gianluigi Forloni, PhD (2), Giovanni Frisoni, MD (1), on behalf of the PharmaCog Consortium presented by Martina Bocchetta, MS  
(1) Laboratory of Epidemiology and Neuroimaging, IRCCS Fatebenefratelli, Brescia, Italy, (2) Department of Neuroscience, Mario Negri Institute for Pharmacological Research, Milano, Italy, (3) Biomedical Engineering Department, Mario Negri Institute for Pharmacological Research, Bergamo, Italy, (4) Eli Lilly, Lilly Research Centre, Windlesham, Surrey, UK, (5) CNS Research, Hoffmann-La Roche AG, Basel, CH, (6) GlaxoSmithKline, Gunnels Wood Road, Stevenage SG1 2NY, UK
Thursday, November 14th

PRECLINICAL STUDIES IN ALZHEIMER’S DISEASE - California Ballroom C

2.15 p.m OC21 - A novel peptide derived from the Cdk5 regulator p35, crosses blood brain barrier and rescues phenotypes of Alzheimer’s disease model mice
Harish C. Pant, MD, PhD, CPR Division, NINDS, NIH, Bethesda, MD USA

2.30 p.m OC22 - Does atorvastatin or telmisartan alter CSF memantine kinetics? A study in normal and STZ-induced rat model of Alzheimer
Omnia Nayel, MD, PhD (1), Maha El-Tohamy, PhD (2), Wessam El Hadidy, MD, PhD (3)
(1) Pharmacology department, Faculty of Medicine, King Saud University, Riyadh, KSA, (2) Chemistry department, Faculty of Science, King Saud University, Riyadh, KSA, (3) Pharmacology department, Medical Research Institute, Alexandria University, Alexandria, Egypt

2.45 p.m OC23 - MultiTEP platform based AD vaccine immunogenic in rabbits and monkeys
Hayk Davtyan, PhD (1), Irina Petrushina, PhD (2), Claire F. Evans, PhD (3), Armine Hovakimyan (1), Arpine Davtyan (1), Drew Hannaman (3), David H.Cribbs, PhD (2,4), Anahit Ghochikyan, PhD (1), Michael G.Agadjanyan, PhD (1,2)
(1) Department of Molecular Immunology, Institute for Molecular Medicine, Huntington Beach, CA, USA, (2) Institute for Memory Impairments and Neurological Disorders, University of California at Irvine, Irvine CA, USA, (3) Ichor Medical Systems, San Diego, CA, USA, (4) Department of Neurology, University of California at Irvine, Irvine, CA, USA

3.00 p.m - 3.45 p.m PARALLEL SESSIONS: ORAL COMMUNICATIONS

3.00 - 3.45 p.m California Ballroom AB
COGNITIVE AND IMAGING ASSESSMENT FOR CLINICAL TRIALS

3.00 p.m OC24 - Improving measurement of change and demonstrating clinical meaningfulness in Alzheimer’s clinical trials
William R. Shankle, MS, MD (1,4), Junko Hara, PhD (1,2), Dennis Fortier, MS, MBA (1)
(1) Medical Care Corporation, Newport Beach, CA, (2) Shankle Clinic, Newport Beach, CA, (3) Memory and Cognitive Disorders Program, Hoag Neurosciences Institute, Newport Beach, CA, (4) Dept. of Cognitive Sciences, University of California, Irvine, CA

3.15 p.m OC25 - Biomarkers and Cognition in Amyloid-positive and Amyloid-negative ADNI MCI Subjects: Implications for AD Therapeutic Trials
Richard A Margolin MD (1), Randolph D Andrews MS (2), Michael Ropacki PhD (1), Ana S Lukic PhD (2), Stephen Salloway MD (3), Reisa Sperling MD, MMSc (4), H Robert Brashear MD (1), Mark E Schmidt MD (6), Enchi Liu PhD (1), Dawn C Matthews MS, MBA (2) for the Alzheimer’s Disease Neuroimaging Initiative
(1) Janssen Alzheimer Immunotherapy LLC, South San Francisco, CA, USA; (2) ADM Diagnostics LLC, Chicago, IL, USA; (3) Butler Hospital, The Warren Alpert Medical School of Brown University, Providence, RI, USA; (4) Departments of Neurology and Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA; Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, MA, USA; (6) Janssen Research and Development, Beerse, Belgium

3.30 p.m OC26 - Cognitive decline, hippocampal atrophy and amyloid accumulation in preclinical and prodromal AD: Clinical trial implications
Paul Maruff, PhD (1,2,6), Yen Ying Lim (2), Robert H.Pietrzak (3), Kathryn A.Ellis (4,6), Colin L.Masters (2,4,6), Christopher C.Rowe (5,6)
(1) CogState Ltd, (2) The Florey Institute of Neuroscience and Mental Health, Parkville, Victoria, Australia, (3) Yale University Medical School, (4) The University of Melbourne, (5) Department of Medicine, Austin Health, The University of Melbourne, Heidelberg, Victoria, Australia, (6) For the AIBL Research Group
PET IMAGING OF TAU PATHOLOGY - California Ballroom C

3.00 p.m  OC27 - PET imaging of tau pathology in patients with Alzheimer’s disease using 18F-THK5117
Nobuyuki Okamura (1), Shozo Furumoto (2), Ryuichi Harada (1), Katsutoshi Furukawa (3), Aiko Ishiki (3), Naoki Tomita (3), Ren Iwata (2), Manabu Tashiro (2), Kazuhiko Yanai (1,2), Hiroyuki Arai (3), Yukitsuka Kudo (4)
(1) Department of Pharmacology, Tohoku University School of Medicine, Sendai, Japan, (2) Cyclotron and Radioisotope Center, Tohoku University, Sendai, Japan, (3) Department of Geriatrics and Gerontology, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan, (4) Clinical Research, Innovation and Education Center, Tohoku University Hospital, Sendai, Japan

3.15 p.m  OC28 - Tau PET, amyloid PET and cognitive performance
Keith A Johnson, M.D., J. Alex Becker, Ph.D., Dorene Rentz, Psy.D., Aaron Schultz, Ph.D., Marlie Philossaint, Jonathan Alverio, Kelly Judge, Neil Vasdev, Ph.D., Thomas Brady, M.D., Bradley Hyman, M.D., Ph.D., Reisa A. Sperling, M.D
Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA

3.30 p.m  OC29 - Preliminary Analysis of PET Scans using the Tau Imaging Tracer [F-18]T807 (AV-1451) in Alzheimer’s Disease
Mark Mintun (1), Abhinay Joshi (1), Sergey Shcherbinin (2), Adam J. Schwarz (2), Ming Lu (1), Michael Pontecorvo (1), Michael Devous (1), Daniel Skovronsky (1), Hartmuth Kolb (1)
(1) Avid Radiopharmaceuticals, Inc., Philadelphia, PA, (2) Eli Lilly & Co, Indianapolis, IN

3.45 p.m  Coffee Break and poster sessions - San Diego Ballroom

4.15 p.m  KEYNOTE - California Ballroom ABC
Moderator: Mike Weiner
The New Era in Alzheimer’s Prevention Research
Eric Reiman MD - Executive Director, Banner Alzheimer’s Institute, Phoenix, AZ - USA

4.45 p.m  SYMPOSIUM 2 - California Ballroom ABC
Rethinking the way to conduct drug trials in Alzheimer’s disease
Moderators: Bruno Vellas (Toulouse), Jeffrey Cummings (Las Vegas), Michael Weiner (San-Francisco), Jacques Touchon (Montpellier)

1. A historical analysis of AD drug trials from 2000 to 2013
   Valérie Legrand, PharmD, ICON, Paris, France

2. Changes needed and consequences conducting drug trials from symptomatic to disease-modifying trials
   Julien Delrieu, MD Toulouse Alzheimer’s Disease Research Clinical Center, Gérontopôle, Toulouse, France

3. New models of clinical trials for Alzheimer’s disease
   Jeffrey Cummings, MD Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas Nevada, Cleveland, Ohio and Weston, Florida

4. Center for drug trials on AD, today limits and perspectives
   Pierre-Jean Ousset, MD, CenGeps Alzheimer Drug Trial Network, Gerontopole, Toulouse France

5. Using the Internet for recruiting, assessing, and monitoring subjects in AD prevention trials: The Brain Initiative
   Mike Weiner, MD, University of California at San Francisco, UCSF

6.30 p.m  Bus departure to the Welcome Reception - Lobby of the Westin Gaslamp

7.00 p.m  Welcome Reception at the Omni San Diego Hotel
## CTAD 2013 Program

**Friday, November 15th**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 8.30 a.m | KEYNOTE - California Ballroom ABC  
Moderator: Paul Aisen  
AD and Down’s syndrome  
William Mobley, Professor and Chair, Department of Neurosciences, University of California at San Diego, CA – USA |
| 9.00 a.m | SYMPOSIUM 3 - California Ballroom ABC  
Agitation and aggression in AD: a new target for drug development  
Susan Abushakra MD (1), Sandrine Andrieu MD (2), Gene Kinney PhD (3), David Sultzer MD (4), Anton P. Porsteinsson MD (5), Constantine Lyketsos MD (6)  
(1) Elan Pharmaceuticals, San Francisco CA, (2) University of Toulouse, France, (3) Prothena Biosciences, San Francisco CA, (4) University of California Los Angeles, Los Angeles CA, (5) University of Rochester, Rochester, NY, (6) Johns Hopkins University, Baltimore MD |
| 10.15 a.m | Coffee Break and poster sessions - San Diego Ballroom |
| 10.45 a.m - 12.15 p.m | PARALLEL SESSIONS: ORAL COMMUNICATIONS  
**COMPOSITE OUTCOMES FOR CLINICAL TRIALS** - California Ballroom AB  
Moderators: John Harrison, Suzanne Hendrix |
| 10.45 a.m | **OC30** - An empirical model of the natural progression of clinical measures of Alzheimer disease  
Suzanne Hendrix, PhD, Stephanie Stanworth, MS, Noel Ellison, MS  
Pentara Corporation, Salt Lake City, UT, USA |
| 11.00 a.m | **OC31** - Composites v2.0: newer measures + earlier population = improved composite  
Michael T. Ropacki, PhD (1,2), Suzanne B. Hendrix, PhD (3), Daniel Ryon Seichepine, PhD (4), Robert Stern, PhD (4)  
(1) Janssen Research & Development, LLC, San Francisco, CA, USA, (2) Neurology Department, Loma Linda University, (3) Pentara Corporation, Salt Lake City, UT, USA, (4) Alzheimer’s Disease Center, Boston University School of Medicine, Boston, MA, USA |
| 11.15 a.m | **OC32** - Optimal composite scale endpoints for clinical trials in mild cognitive impairment and pre-clinical Alzheimer’s disease  
M. Colin Ard, PhD (1), Steven D. Edland, PhD (1,2)  
(1) Department of Neurosciences and (2) Department of Family Preventive Medicine Division of Biostatistics, University of California, San Diego, CA, USA |
| 11.30 a.m | **OC33** - Brief online computerized cognitive battery as a screening tool for clinical trials in MCI and mild dementia due to AD  
Bruce Albala, PhD (1), Paul Maruff, PhD (3), Judith Jaeger, PhD (4), Michelle Gee, PhD (5), Andrew Satlin, MD (1)  
| 11.45 a.m | **OC34** - Comparing computerized versus conventional neuropsychological tests of memory: factors influencing sensitivity to donepezil  
Judith Jaeger (1,2,3), Adina Soaita (1), Joanne Gale (1), Kristin Hannesdottir (4)  
(1) CogState, Inc. New Haven, CT, USA, (2) Albert Einstein Coll of Medicine, Bronx, NY, USA, (3) University of Manchester, UK, (4) AstraZeneca Research & Development, Cambridge, MA, USA |
| 12.00 p.m | **OC34bis** - The INSIGHT study: Conceptual considerations on the preclinical states of AD  
Bruno Dubois, MD, PhD (1), Harald Hampel, MD, PhD (2)  
(1) Department of Neurology, Salpétrière Hospital, Paris, France, (2) Department of Psychiatry, Alzheimer Memorial Center, Ludwig-Maximilian University, Munich, Germany |
**CTAD 2013 Program**
Friday, November 15th

**NEUROIMAGING PET FOR CLINICAL TRIALS - California Ballroom C**

**Moderators:** Dorene Rentz, Stephen Salloway

**10:45 a.m OC35** - A multivariate FDG PET classifier metric improves prediction of cognitive change in Normals, MCI and AD patients
Lisa Mosconi, PhD (1,2,3), Randolph D Andrews, MS (1,2), Ana S Lukic, PhD (1,4), Miles N Wernick (1,4,5), Stephen C Strother (1,4,5), Enchi Liu (7), Richard Margolin (7), Mark E Schmidt (8), Dawn C Matthews (1,2), and the Alzheimer’s Disease Neuroimaging Initiative
(1) ADM Diagnostics, Chicago, IL USA, (2) Abiant Inc., Grayslake, IL USA, (3) Department of Psychiatry, New York University School of Medicine, New York, NY, USA, (4) Predictek Inc., Chicago, IL USA, (5) Illinois Institute of Technology, Chicago, IL USA, (6) Rotman Research Institute, Baycrest, Toronto, ON, Canada, (7) Janssen Alzheimer Immunotherapy, South San Francisco, CA USA, (8) Janssen Research and Development, Beerse, Belgium

**11:00 a.m OC36** - Longitudinal morphometric characterization of mild cognitive impairment patients in WP5 Pharmacog/E-ADNI study: preliminary data
Martina Bocchetta, MS, on behalf of the PharmaCog Consortium
Laboratory of Epidemiology, Neuroimaging and Telemedicine, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy

**11:15 a.m OC37** - Validation of the EADC-ADNI harmonized protocol for manual hippocampal segmentation: preliminary results
Martina Bocchetta, MS for the EADC-ADNI group for the Harmonization of the Harmonized Protocol
IRCCS S.Giovanni di Dio-Fatebenefratelli, Brescia, Italy

**11:30 a.m OC38** - ETNA3, a clinical randomized study assessing 3 cognitive-oriented therapies in Alzheimer’s disease
Hélène Amieva, PhD (1,2), Jean-François Dartigues, MD, PhD (1,2)
(1) INSERM U897 Epidemiology and Biostatistics Unit, Bordeaux, France, (2) CMRR Bordeaux-Pellegrin, France

**11:45 a.m OC39** - Novel cognitive outcomes for preclinical Alzheimer’s disease prevention trials
Dorene M. Rentz, PsyD (1), Adrian Schembri, DPsych (2), David Salmon, PhD (4), Michael Donohue, PhD (4), Paul Maruff, PhD (2), Paul Aisen, MD (4), Reisa A. Sperling, MD (1)
(1) Departments of Neurology, Massachusetts General Hospital and Brigham and Women’s Hospital, Boston, MA, (2) CogState Ltd, Melbourne, Australia, (3) University of California Irvine, Irvine, CA, (4) University of California at San Diego, San Diego, CA

**12:00 p.m OC40** - A dose-response relationship between computerized cognitive training and global cognition in older adults
Amit Lampit, Mag (FH) (1), Hariharan Hallock, MA (1), Rebecca Moss, MA (1), Sindy Kwok, PGDipPsych (1), Michael Rosser, BA, (2), Matthew Lukjanenok, PGDipPsych (1), Alana Kohn, PGDipPsych (1), Sharon Naismith, DPych (Neuro) (3), Henry Brodaty, MBBS, DSc, FRANZCP (4), Michael Valenzuela, PhD, MBBS (Hons) (1)
(1) Regenerative Neuroscience Group, Brain and Mind Research Institute, University of Sydney, Sydney, Australia, (2) School of Psychology, University of New South Wales, Sydney, Australia, (3) Clinical Research Unit, Brain and Mind Research Institute, University of Sydney, Sydney, Australia, (4) Dementia Collaborative Research Centre-Assessment and Better Care, School of Psychiatry, Faculty of Medicine, University of New South Wales, Sydney, Australia

**12:15 p.m** Lunch Break and poster sessions - San Diego Ballroom

<table>
<thead>
<tr>
<th>1.15 p.m - 3.15 p.m</th>
<th>PARALLEL SESSIONS: ORAL COMMUNICATIONS</th>
</tr>
</thead>
<tbody>
<tr>
<td>California Ballroom AB</td>
<td>TREATMENT ASSESSMENT FOR CLINICAL TRIALS</td>
</tr>
<tr>
<td>California Ballroom C</td>
<td>BIOMARKERS FOR CLINICAL TRIALS</td>
</tr>
</tbody>
</table>

**TREATMENT ASSESSMENT FOR CLINICAL TRIALS - California Ballroom AB**

**Moderators:** Steve Ferris, Anton Porsteinsson

**1:15 p.m OC41** - The API Colombia study: A prevention study in ADAD that will pave the way for prevention studies in sporadic AD
(1) Genentech, South San Francisco, CA, USA, (2) Banner Alzheimer’s Institute, Phoenix, AZ, USA, (3) Pentara Corporation, Salt Lake City, UT, USA, (4) Grupo de Neurociencias de Antioquia, Universidad de Antioquia, Medellin, Colombia
CTAD 2013 Program

Friday, November 15th

TREATMENT ASSESSMENT FOR CLINICAL TRIALS - California Ballroom AB

1.30 p.m  OC42 - A phase 2 study to investigate the effects of SAR110894 on cognition, daily function, apathy and sleep in mild to moderate Alzheimer’s disease patients
Jeanne Stemmelin (1), Stéphane Kirkesseli (1), Renata Martinova (1), Raphael Bejuit (1), Valérie Corp-dit-Genti (1), Gilmour Morrison (2), Blandine Nembo (1), Christine Fauveau (1), Hervé Bester (1), Agnès Menut (1), Sophie Claudel (1), John Alam (1)
(1) Sanofi Research and Development, Chilly Mazarin, France, (2) Covance, Alnwick, UK

1.45 p.m  OC43 - CANCELLED

2.00 p.m  OC44 - A novel active immunization against C-terminal region of Aβ enters clinical trial phase I
Pedro Pesini, PhD, Manuel Sarasa, PhD
Aranclon Biotech Ltd. Zaragoza, Spain

2.15 p.m  OC45 - Anti-amyloid-β therapy of Alzheimer disease (AD) patients by omega-3 supplementation: Recovery of innate immunity
Milan Fiala, M.D (1), Verna Porter, M.D (2), Marc Dubourdeau, Ph.D (3)
(1) Surgery Department, UCLA, Los Angeles, CA, USA, (2) Neurology Department, UCLA, Los Angeles, CA, USA, (3) Ambiotic SAS, Toulouse, France

2.30 p.m  OC46 - Safety and efficacy of ORM-12741 on cognitive and behavioral symptoms in patients with Alzheimer’s disease: A randomized, double-blind, placebo-controlled, parallel group, multicenter, proof-of-concept 12 week study
K. Wesnes (1), J.O. Rinne (2,3), J. Hänninen (4), M. Murphy (5), H. Riordan (5), J. Rouru (4), and the ALPO Study Group
(1) Bracket Global, Goring-on-Thames, UK, (2) Turku PET Centre, (3) Turku University Central Hospital, Turku, Finland, (4) Orion Pharma, Turku, Finland, (5) World Wide Clinical Trials, King of Prussia, PA, USA

2.45 p.m  OC47 - Intravenous Bapineuzumab in mild to moderate Alzheimer’s disease: Results from two double-blind, placebo-controlled phase 3 trials
Prisca Lucas, PharmD, PhD (1), David Li, PhD (2), Kasia Lobello, MD (2), Enchi Liu, PhD (3), H Robert Brashear, MD (3), Scot Styren, PhD (4), on behalf of the study 3133K1-3000/3001 Investigators
(1) Pfizer PGRD, Paris, France, (2) Pfizer Inc, Collegeville, PA, USA, (3) Janssen Alzheimer Immunotherapy Research & Development, LLC, South San Francisco, CA, USA, (4) Pfizer Inc, Groton, CT, USA

3.00 p.m  OC48 - Relationship between cognitive and functional progression in patients with mild Alzheimer’s disease
Hong Liu-Seifert, PhD (1), Eric Siemers, MD (1), Karen Sundell, BS (1), Karen Price, PhD (1), Baoguang Han, PhD (1), Shannon Gardell, PhD (2)
(1) Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN, USA, (2) iVentiv Health Clinical, Somerset, NJ, USA

BIOMARKERS FOR CLINICAL TRIALS - California Ballroom C
Moderators: Cristina Sampaio, Scott Turner

1.15 p.m  OC49 - Detection of ligand bound to β Amyloid in the lenses of for Alzheimer’s disease diagnosis
Charles Kerbage, PhD (1), Carl H. Sadovsky, MD (2), Pierre N. Tariot, MD (3), Marc Agronin, MD (4), Gustavo Alva, MD (5),1*
Dennis Nilan (1), Anne Cameron, PhD (1), Gerald D. Cagle, PhD (1)
(1) Cognoptix, Inc., Acton, MA, USA, (2) Premiere Research Institute and Nova Southeastern University, West Palm Beach, FL, USA, (3) Banner Alzheimer’s Institute, Phoenix, AZ, USA, (4) Miami Jewish Health Systems, Miami, FL, USA, (5) ATP Clinical Research Inc. Costa Mesa, CA, USA

1.30 p.m  OC50 - Prediction of cognitive and functional decline in patients with mild cognitive impairment by multiple brain volumes automatically extracted from structural MRI
Robin Wolz, PhD (1,2), Peng Yu, PhD (3), Adam J.Schwarz, PhD (3), Kate McLeish, PhD (1), Daniel Rueckert, PhD (1,2), Derek Hill, PhD (1)
(1) IXICO Ltd, London, UK, (2) Imperial College London, London, UK, (3) Eli Lilly and Company, Indianapolis IN, USA
1.45 p.m  **OC51** - Resting-state functional MRI standardization for multi-center clinical trials  
David Scott, PhD (1), Ping-Chun Chiao, PhD (2), Jeff Sevigny, MD (2), Joyce Suhy, PhD (1)  
(1) Synarc, Inc, Newark, CA, USA, (2) Biogen Idec, Inc Weston, MA, USA

2.00 p.m  **OC52** - Event related potentials: a cognitive biomarker for diagnosis of early-stage Alzheimer disease  
Marco Cecchi, PhD (1), Shauna Burkholder, MS (1), Sarah Berg, PhD (1), Carl Sadowsky, MD (2), Paul Solomon, PhD (3), P.Murali Doraiswamy, MBBS (4), Charles Smith, MD (5), Gregory Jicha, MD, PhD (5), Steven Arnold, MD (6), Bradley Folley, PhD (7), David Casey, MD (8), Andrew E.Budson, MD (9)  
(1) Neuronetrix, KY, USA, (2) Premiere Research Institute, FL, USA, (3) The Memory Clinic, VT, USA, (4) Psychiatry Department, Duke University, NC, USA, (5) Neurology Department, University of Kentucky, KY, USA, (6) Psychiatry Department, University of Pennsylvania, PA, USA, (7) Norton Neuroscience, Norton Healthcare, KY, USA, (8) Psychiatry Department, University of Louisville, KY, USA, (9) Boston Center for Memory, MA, USA

2.15 p.m  **OC53** - In contrast to lower brain glucose uptake, brain ketone uptake is unchanged in mild Alzheimer’s disease: A dual tracer PET study comparing 18F-FDG and 11Cacetoacetate  
Alexandre Castellano, PhD (1), Scott Nugent (1), Melanie Fortier (1), Nancy Paquet (2), Christian Bocti (1), Martin Lepage (3), Eric Turcotte (3), Tamas Fulop (1), Stephen Cunnane (1)  
(1) Research Center on Aging, CSSS-IUGS, (2) Clinical Research Center, (3) Sherbrooke Molecular Imaging Center, Université de Sherbrooke, Sherbrooke, Québec, Canada

2.30 p.m  **OC54** - A panel of ten plasma lipids identifies antecedent memory impairment in older adults  
Massimo S. Fiandaca  
Departments of Neurology and Neuroscience, Georgetown University Medical Center, Washington, DC, USA

2.45 p.m  **OC 55** - The Aβ oligomer count in CSF is a biomarker for Alzheimer’s disease  
Lei Wang-Dietrich, PhD (1), Susanne Aileen Funke, PhD (1), Eva Birkmann, PhD (1,2), Dieter Willbold, PhD (1,2)  
(1) Research Centre Juelich, Juelich, Germany, (2) Heinrich-Heine-University, Duesseldorf, Germany

3.00 p.m  **OC56** - Reconstruction of entire chronological changes of multiple biomarkers in Alzheimer’s disease from ADNI data by modeling: Significance of classification by Amyloid beta in CSF  
Akihiro Hisaka, PhD (1), Takaa Kishida, MS (2), Masashi Honma, MS (2), Kazutoshi Yokozuka, MS (3), Hidefumi Kasai, MS (3), Takashi Moritoyo, MD, PhD (4), Yoshihiro Arakawa, PhD (5), Takeshi Watabu, MD, PhD (6), Hiroshi Suzuki, PhD (2)  
(1) Pharmacology and Pharmacokinetics, The University of Tokyo Hospital, Tokyo, Japan, (2) Department of Pharmacy, The University of Tokyo Hospital, Tokyo, Japan

3.15 p.m  **Coffee Break and poster sessions** - San Diego Ballroom
CTAD 2013 Program

Friday, November 15th

3.45 p.m  KEYNOTE - California Ballroom ABC
Moderator: Jacques Touchon
Designing drug trials taking into account neuropsychiatric symptoms of AD
Jeffrey Cummings, MD - Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV – USA

4.15 p.m  SYMPOSIUM 4 - California Ballroom ABC
Internet screening of cognition as a method for recruiting to clinical trials in prodromal Alzheimer’s disease
Moderators: John Harrison, PhD, Metis Cognition, Wiltshire, UK

   Paul Maruff PhD (1), Judy Jaeger, PhD (1), Yen Ying Lim, PhD (2), Ara Khachaturian, PhD (3)

2. Does internet screening of cognition deliver appropriate subjects for trials of prodromal AD? A perspective from industry
   Bruce Albala, PhD (1), Michelle Gee, PhD (1) Andrew Satlin, MD (1)
   (1) Eisai, Woodcliff Lake, NJ, USA

3. Can internet based cognitive screening deliver appropriate patients to clinical research units for trials in prodromal AD?
   Larry Ereshefsky, PharmD
   PAREXEL International, and California Clinical Trials Medical Group, Glendale, CA, USA

5.30 p.m  KEYNOTE - California Ballroom ABC
Moderator: Mathieu Ceccaldi
Ethical issues in AD prevention trials: genetics, biomarkers and treatment risk
Serge Gauthier, MD, FRCPC, McGill Center for Studies in Aging, Douglas Mental Health Research Institute, Montreal, Canada
CTAD 2013 Program

Saturday, November 16th

8.00 a.m  KEYNOTE - California Ballroom AB
Moderator: Paul Aisen
Novel immunotherapy approaches
David Holtzman, MD - Professor and Chairman of Neurology, Associate Director of the Alzheimer’s Disease Research Center, Washington University in St. Louis, MO – USA

8.30 a.m - 10.00 a.m  PARALLEL SESSIONS

California Ballroom AB
8.30 - 9.45 a.m
SYMPOSIUM 5
Metabolic dysregulation in the Alzheimer brain: challenges and opportunities

California Ballroom C
8.30 - 9.00 a.m
BIOMARKERS FOR CLINICAL TRIALS
9.00 - 10.00 a.m
PRECLINICAL STUDIES IN AD

8.30 a.m  SYMPOSIUM 5 - California Ballroom AB
Metabolic dysregulation in the Alzheimer brain: challenges and opportunities
Moderator: Samuel T Henderson, PhD,
AcceraInc, Broomfield, CO, USA

1. Induced ketosis in mild to moderate Alzheimer’s disease
Samuel T Henderson, PhD
AcceraInc, Broomfield, CO, USA

2. Fuel-specific regional metabolic deterioration in the brain in the elderly and in early Alzheimer’s disease
Stephen Cunnane, PhD1, Scott Nugent, MSc1, Alex Castellano, MSc1, Kewei Chen, PhD2, Eric Turcotte, MD, Phd1, TamásFULOP, MD, Phd1, Eric Reiman, MD, Phd2
(1) Research Center on Aging and Department of Medicine, University of Sherbrooke, Sherbrooke, Quebec, Canada
(2) Banner Alzheimer’s Institute, Phoenix, AZ, USA

3. Dietary intervention to ameliorate neurocognitive decline with aging
Robert Krikorian, PhD
Department of Psychiatry & Behavioral Neuroscience, University of Cincinnati Academic Health Center, Cincinnati, OH, USA

BIOMARKERS FOR CLINICAL TRIALS - California Ballroom C
Moderators: Robert Rissman, Reisa Sperling

8.30 a.m  OC57 - Alzheimer’s disease biomarkers as outcome measures for clinical trials in MCI
Annapaola Prestia, PsyD (1), Anna Caroli, PhD (1,2), Sara Wade, PhD (3,4), Kewei Chen, PhD (4), Napatkamon Ayutyanont, PhD (4), Susan M. Landau, PhD (5), Cindee M. Madison, MS (5), Cathleen Haense, MD (6), Karl Herholz, MD (7), Eric M. Reiman, MD (4), William J. Jagust, MD (5), Giovanni B. Frisoni, MD (1), Martina Bocchetta, MS
(1) Laboratory of Epidemiology and Neuroimaging -IRCCS S. Giovanni di Dio-FBF, Brescia, Italy, (2) Medical Imaging Unit, Biomedical Engineering Department, IRCCS Istituto di Ricerca Farmacologiche Mario Negri, Bergamo, Italy, (3) Department of Engineering, University of Cambridge, Cambridge, UK, (4) Department of Decision Science, Bocconi University, Milan, Italy, (5) Banner Alzheimer’s Institute, Phoenix (AZ), USA, (6) Helen Wills Neuroscience Institute, University of California, Berkeley (CA), USA, (7) Hannover Medical School, Clinic for Nuclear Medicine, Hannover, Germany, (8) University of Manchester, UK

8.45 a.m  OC58 - Factors that influence use of plasma Amyloid beta as a biomarker of AD
Robert Rissman, Michael Donohue, Setareh Moghadam, Chung-Kai Sun, Steven Edland, Paul Aisen
Department of Neurosciences, University of California San Diego, San Diego, CA, USA
CTAD 2013 Program

Saturday, November 16th

PRECLINICAL STUDIES IN AD - California Ballroom C
Moderators: Ron Petersen, Jacques Touchon

9.00 a.m  OC59 - Dissecting the anatomy of computerised cognitive training: systematic review and meta-analysis of RCTs in older adults
Amit Lampit, Mag(FH), Hariharan Hallock, MA, Michael Valenzuela, PhD, MBBS(Hons)
Regenerative Neuroscience Group, Brain and Mind Research Institute, University of Sydney, Sydney, Australia

9.15 a.m  OC60 - A centrally active ACE inhibitor promotes signs of hippocampal neuroregeneration in the Tg2576 model of Alzheimer’s disease
Andreas Langer, PhD, Said AbdAlla, PhD, Xuebin Fu, MSc, Ursula Quitterer, PhD
Molecular Pharmacology Unit, Swiss Federal Institute of Technology, Zurich, Switzerland

9.30 a.m  OC61 - The anti-amyloid chaperone BRICHOS efficiently prevents amyloid β-peptide CNS toxicity in Drosophila melanogaster
Erik Hermansson, PhD, Bengt Winblad, MD, PhD (1), Jan Johansson, MD, PhD (1,2,3), Jenny Presto, PhD (1)
(1)ki Alzheimer Disease Research Centre, Dept NVS, Karolinska Institutet, Stockholm, Sweden, (2)Department of Anatomy, Physiology and Biochemistry, Swedish University

9.45 a.m  OC62 - Presenilin/γ-secretase function to cleave pathological Aβ42/43
Masayasu Okochi, MD, Shinji Tagami, MD, Kanta Yanagida, PhD, Yasuo Ihara, MD
Osaka University, Osaka, Japan

10.00 a.m  Coffee Break and poster sessions - San Diego Ballroom

10.30 a.m  SYMPOSIUM 6 - California Ballroom AB
Clinical trials in early stage Alzheimer’s disease: CSF biomarkers symposium
Moderator: Jacques Touchon, MD, PhD, Montpellier University Hospital, Memory Center and INSERM U1061, Montpellier, France

1. Brain amyloid-beta peptides dynamics in Alzheimer’s disease
Randall Bateman, MD, PhD
Washington University, School of Medicine, St Louis, Missouri, USA

Christophe Hirtz, PhD
INSERM U1040 and Institut de Recherche en Biothérapie, Laboratoire de Biochimie Protéomique Clinique, Montpellier, France

3. Relevance of cerebrospinal fluid Alzheimer’s disease biomarkers in clinical practice
Audrey Gabelle, MD, PhD
Department of Neurology, Memory Center, Montpellier University Hospital and INSERM U1040, France
Themes

THEME: CLINICAL TRIALS METHODOLOGY ..................................................... p. 19
P1 to P11

THEME: CLINICAL TRIALS RESULTS .......................................................... p. 20
P12 to P18

THEME: CLINICAL TRIALS: IMAGING ......................................................... p. 21
P19 to P31

THEME: CLINICAL TRIALS BIOMARKERS ................................................. p. 23
P32 to P44

THEME: CLINICAL TRIALS: COGNITIVE ENDPOINTS ......................... p. 24
P45 to P47

THEME: CLINICAL TRIALS: COGNITIVE ASSESSMENTS ...................... p. 25
P48 to P54

THEME: HEALTH ECONOMICS AND CLINICAL TRIALS ...................... p. 25
P55 to P56

THEME: EPIDEMIOLOGY AND CLINICAL TRIALS ................................ p. 26
P57 to P58

THEME: ANIMAL MODELS AND CLINICAL TRIALS ............................. p. 26
P59 to P64

THEME: NEW THERAPIES AND CLINICAL TRIALS ............................... p. 27
P65 to P76
POSTER PRESENTATIONS

THEME: CLINICAL TRIALS METHODOLOGY

P1  THERAPEUTIC STRATEGIES TO PREVENT ALZHEIMER’S DISEASE PATHOGENESIS USING FLUORESCENT CONJUGATED POLYMER
Parameswar K. Iyer, PhD, B. Muthuraj, MSc, Atul K.Dwivedi, PhD, Sameer Hussain, MSc
Department of Chemistry, Indian Institute of Technology, Guwahati, Assam – INDIA

P2  CHOOSING ALZHEIMER’S DISEASE PREVENTION TRIAL POPULATIONS
Joshua D. Grill, PhD (1), Sarah Monsell (2)
(1) Mary Easton Center for Alzheimer’s Disease Research, Department of Neurology, UCLA, Los Angeles, CA, (2) National Alzheimer’s Coordinating Center, University of Washington, Seattle, WA

P3  DOES STUDY PARTNER TYPE IMPACT THE RATE OF ALZHEIMER’S DISEASE PROGRESSION?
Joshua D. Grill, PhD (1), Yan Zhou, PhD (1), Jason Karlawish, MD (3), David Elashoff, PhD (1,2)
(1) Mary S. Easton Center for Alzheimer’s Disease Research, Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA, (2) Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, (3) University of Pennsylvania, Perelman School of Medicine, Departments of Medicine, and Medical Ethics and Health Policy, Penn Memory Center, Philadelphia, PA

P4  SELECTING ACCEPTABLE CAREGIVER INFORMANTS FOR AD CLINICAL TRIALS : IS MORE CARE NEEDED ?
Priscilla Samuelson, RN and David S. Miller, MD, MA
Bracket, Wayne, PA, USA

P5  PREDICTORS OF PLACEBO RESPONSE IN SUBJECTS WITH MILD-TO-MODERATE ALZHEIMER’S DISEASE: FINDINGS FROM 12-WEEK, PHASE 2A CLINICAL TRIALS
Teresa Buracchio, MD, Andreas Meier, MD, Ferenc Martenyi, MD, Qi Tang, PhD, Laura Gault, MD, PhD
AbbVie Inc., North Chicago, IL, USA

P6  SUBJECTS WITH MILD-TO-MODERATE ALZHEIMER’S DISEASE EXHIBIT EVIDENCE OF PRACTICE EFFECTS ON REPEATED MEASURES OF THE ALZHEIMER’S DISEASE ASSESSMENT SCALE-COGNITIVE SUBSCALE AND THE MINI-MENTAL STATUS EXAMINATION
Andreas Meier, MD, Teresa Buracchio, MD, Ferenc Martenyi, MD, Qi Tang, PhD, Laura Gault, MD, PhD
AbbVie Inc., North Chicago, IL, USA

P7  PRACTICAL EXPERIENCE OF CONSENSUS DETERMINATION IN A GLOBAL, PHASE 2 ALZHEIMER’S DISEASE CLINICAL TRIAL (CN156-018)
Matthew Gabel, PhD (1), Vladimir Coric, MD (2), Robert Berman, MD (2), Jesse Cedarbaum, MD (2), Howard Chertkow, MD (3), Rajan Duara, MD (4), Stephen Kaplita, PhD (2), Christine Moore, PhD (5), Norman Foster, MD (6)
(1) Department of Political Science, Washington University, St. Louis, MO, USA, (2) Neuroscience Global Clinical Research, Bristol-Myers Squibb, Wallingford, CT USA (3) Lady Davis Institute, Sir Mortimer B. Davis Jewish General Hospital, Montreal, PQ CA, (4) Department of Neurology, McGill University School of Medicine, Montreal, Quebec CA, (5) Wien Center for Alzheimer’s Disease and Memory Disorders, Mt. Sinai Medical Center, Miami Beach, FL USA, (6) InVentiv Health Clinical, Cary, NC USA, (7) Center for Alzheimer’s Care, Imaging, and Research and Department of Neurology, University of Utah, Salt Lake City, UT USA

P8  OPTIMIZING THE ANALYSIS OF PHASE 2 AND PHASE 3 CLINICAL TRIALS IN ALZHEIMER’S DISEASE
Stephanie Stanworth, MS, Noel Ellison, MS, Leah Garriott, MS, Suzanne Hendrix, PhD
Pentara Corporation, Salt Lake City, UT – USA

P9  ADCS ELECTRONIC DATA CAPTURE (EDC) - SMART ELECTRONIC CASE REPORT FORM (ECRF) FRAMEWORK
Gustavo A. Jimenez-Maggiora, MBA, Ronald G. Thomas, PhD, Jia-shing So, BS, Stefania Bruschi, MS, Hongmei Qiu, BS, Phuoc Hong, BA, Paul S. Aisen, MD
Neurosciences department, University of California at San Diego, La Jolla, CA, USA

P10 DOSE SELECTION FOR ELND005 (SCYLLO-INOSITOL) IN NEUROPSYCHIATRIC CLINICAL TRIALS: USE OF MODELING AND SIMULATIONS (M&S) OF POPULATION PHARMACOKINETIC MODEL TO ESTIMATE TARGET DRUG EXPOSURES
Earvin Liang, PhD (1), Michelle Green, PhD (2), Matthias Kurth, MD, PhD (1), J Patrick Kesslak, PhD (1), Susan Abushakra, MD (1)
(1) Elan Pharmaceuticals, Inc., San Mateo, CA, USA, (2) Pharsight, a Cartara Corporation, Sunnyvale, CA, USA
POSTER PRESENTATIONS

THEME: CLINICAL TRIALS METHODOLOGY

P11 RETROSPECTIVE REVIEW OF SAFETY AND TOLERABILITY OF CONTINUOUS CEREBROSPINAL FLUID (CSF) COLLECTIONS DURING PHASE 1 PHARMACOKINETIC/PHARMACODYNAMIC STUDIES IN HEALTHY VOLUNTEERS AND PATIENTS

Hakop Gevorkyan (1), Brett A. English (1,3), David Han (1), Lev Gertsik (1), Melody Avakian (2), Jasmine Pauly (2), Stanford S. Jhee (2), Larry Ereshefsky (2,4)

(1) California Clinical Trials Medical Group, (2) PAREXEL International, (3) Glendale, CA, Dept. of Pharmacology, (4) Vanderbilt University Medical Center; Nashville, TN, Glendale, CA, (4) University of Texas College of Pharmacy, Austin, TX

THEME: CLINICAL TRIALS RESULTS

P12 SENSITIVITY TO CHANGE OF VALIDATED ALZHEIMER’S DISEASE INSTRUMENTS IN AN ASIAN SAMPLE

Joan Shen MD PhD (1), Qi Shen MD PhD (1), Jin-Shei Lai PhD (2), Jennifer Beaumont (2), Holly Yu (1), Zhenxin Zhang MD (3), Huaili Wang MD PhD (4), Seongyoon Kim MD (5), Timothy Kwok MD (6), Christopher Chen MD (7), Shuu-Jiun Wang MD (8), Dongyoung Lee MD (9), John Harrison PhD (10), Jeffrey Cummings MD* (11)

(1) Pfizer Inc. USA, (2) Feinberg School of Medicine at Northwestern University, USA, (3) Peking Union Medical College Hospital, China, (4) The Sixth Hospital of Peking University, China, (5) Asan Medical Center, South Korea, (6) Prince of Wales Hospital, Hong Kong, China, (7) National University Hospital, South Korea, (8) Taipei Veterans General Hospital, Taiwan, (9) Seoul National University Hospital. South Korea, (10) Metis Cognition Ltd. Dept. of Medicine, Imperial College, London, UK, (11) Cleveland Clinic Lou Ruvo Center for Brain Health, USA

P13 UNDIAGNOSED PRE-DIABETES OR DIABETES IS HIGHLY PREVALENT IN INDIVIDUALS WITH MILD-MODERATE DEMENTIA DUE TO ALZHEIMER’S DISEASE

R.S.Turner (1), S.Craft (2), P. Aisen (3)

(1) Georgetown University, Washington, D.C., (2) Wake Forest University, Winston-Salem, N.C., (3) University of California, San Diego, CA, USA

P14 HIGH VARIABILITY AND LACK OF CHANGE ON THE ADAS-COG: PLACEBO ANALYSES OF THE CODR DATABASE

Danielle Popp, PhD (1), Lori M. Garizio, MS (1), Peter Boehm, MS (1), Christopher Randolph, PhD (1,2)

(1) MedAvante, Inc., (2) Department of Neurology, Loyola University Medical Center

P15 AZD3293 A NOVEL BACE1 INHIBITOR: EFFECT ON PLASMA AND CSF Aβ PEPTIDES FOLLOWING SINGLE AND MULTIPLE-DOSE ADMINISTRATION

Samantha Budd Haeberlein, PhD (1), Robert Alexander, MD (1), Alan Kugler, PhD (1), Gvido Cebers MD, PhD (1), Naidong Ye, PhD (1), Tina Olsson, PhD (1), Doug Burdette, PhD (1), David Han, MD (2), Ronald Goldwater, MD (2), Larry Ereshefsky PharmD, FCCP (2)

(1) AstraZeneca, Cambridge, MA, USA, (2) PAREXEL International Early Phase, Glendale, CA, USA

P16 EFFECT OF MEMANTINE ON THE PROGRESSION OF DRIVING IMPAIRMENT IN PATIENTS WITH MILD ALZHEIMER’S DISEASE

Peter J. Holland, MD, DFAPA, FACOEM (1), Ruth M. Tappen, EdD, RN, FAAN (2), Lori Fisher, MA (3), Anna Lisa Curtis, BA (4), Jeff Apter, MD (5)

(1) Department of Integrated Medical Science, Charles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton, FL, USA, (2) Christine E. Lynn College of Nursing, Florida Atlantic University, Boca Raton, FL, USA, (3) Department of Integrated Medical Science, Charles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton, FL, USA, (4) Department of Integrated Medical Science, Charles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton, FL, USA, (5) Global Clinical Trials LLC, Princeton, NJ, USA

P17 CHINESE HERBAL MEDICINE IN VASCULAR DEMENTIA: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS

Jing Shi, MD, Wenjia Jian MD, Jingnian Ni, MD, Xuekai Zhang PhD, Mingqing Wei, MD

Department of Neurology, Dongzhimen Hospital, Beijing University of Chinese Medicine

P18 AMYLOID PET SCREENING RESULTS BY APOE E4 STATUS FROM A PHASE 1B CLINICAL STUDY 221AD103 IN PRODROMAL TO MILD AD PATIENTS

Ping Chiao, PhD (1), Joyce Suhy, PhD (2), Jerry Barakos, MD (2), Meredith Burke, PhD (2), Greg Klein, PhD (2), Ajay Verma, MD, PhD (1), Jeff Sevigny, MD (1)

(1) Biogen Idec, Inc Weston, MA, USA, (2) Synarc, Inc Newark, CA, USA
POSTER PRESENTATIONS

THEME: CLINICAL TRIALS: IMAGING

P19 USEFULNESS OF DTI (DIFFUSION TENSOR IMAGE) AS AN EARLY DIAGNOSTIC TOOL FOR SUBJECTIVE MEMORY IMPAIRMENT AND MILD COGNITIVE IMPAIRMENT
Kawon Jung, MD, Dong Won Yang, MD
Department of Neurology, College of Medicine, The Catholic University of Korea, Seoul, Korea

P20 HIPPOCAMPAL VOLUME CHANGE MEASUREMENT: EXPERT MANUAL OUTLINING IS AS REPRODUCIBLE AS THE AUTOMATED METHODS FREESURFER AND FIRST
Philip Scheltens (1,6), Emma R. Mulder (1,2), Remko A de Jong (1,2), Dirk L Knol (3), Ronald A van Schijndel (1,4), Keith S Cover (5), Pieter J Visser (6), Frederik Barkhof (1,2), Hugo Vrenken (2,5) for ADNI7
(1) Image Analysis Center, VU University Medical Center, Amsterdam, The Netherlands, (2) Department of Radiology, VU University Medical Center, Amsterdam, The Netherlands, (3) Department of Epidemiology and Biostatistics, VU University Medical Center, Amsterdam, The Netherlands, (4) Department of Information & Communication Technology, VU University Medical Center, Amsterdam, The Netherlands, (5) Department of Physics and Medical Technology, VU University Medical Center, Amsterdam, The Netherlands, (6) Department of Neurology, VU University Medical Center, Amsterdam, The Netherlands, (7) Alzheimer’s Disease Neuroimaging Initiative (ADNI) database (adni.loni.ucla.edu)

P21 ITALIAN NETWORK FOR AUTOSOMAL DOMINANT ALZHEIMER’S DISEASE AND FRONTOTEMPORAL LOBAR DEGENERATION
Giovanni B. Frisoni, MD (1), Claudio Babiloni, PhD (2), Amalia C. Bruni, MD (3), Elio Scarpini, MD (4), Sandro Sorbi, MD (5), Fabrizio Tagliavini, MD (6), Martina Bocchetta, MS (1), Michela Piovani, PhD (1), Alessandro Padovani, MD, PhD (7)
(1) LENITEM (Laboratory of Epidemiology, Neuroimaging and Telemedicine) IRCCS – S. Giovanni di Dio – Fatebenefratelli Brescia, Italy, (2) Università di Roma “La Sapienza”, Roma, Italy, (3) Centro Regionale di Neurogenetica, Lamezia Terme, Italy, (4) IRCCS Ospedale Policlinico, Milano, Italy, (5) Università di Firenze, Firenze, Italy, (6) IRCCS Fondazione Istituto Neurologico Carlo Besta, Milano, Italy, (7) Università di Brescia, Brescia, Italy

P22 PROVIDING STANDARDIZED LABELS OF THE EADC-ADNI HARMONIZED HIPPOCAMPAL PROTOCOL FOR AUTOMATED ALGORITHM TRAINING
Boccardi M, PhD (1), Bocchetta M, MS (1), Nishikawa M, MD (2), Ganzola R, MS (3), Grothe M, PhD (4), Wolf D, MS (5), Duchesne S, PhD (3), Jack CR Jr, MD (6), Frisoni GB, MD (1)
(1) IRCCS S.Giovanni di Dio-Fatebenefratelli, Brescia, Italy, (2) Kawamura Gakuen Woman's University, Abiko, Japan, (3) Université Laval and Centre de Recherche Université Laval – Robert Giffard, Quebec City, Canada, (4) German Center for Neurodegenerative Diseases (DZNE), Rostock, Germany, (5) University Medical Center Mainz, Mainz, Germany, (6) Mayo Clinic, Rochester, NY, USA

P23 A MAGNETIC RESONANCE SPECTROSCOPY STUDY TO EXPLORE THE EFFECTS OF THE MEDICAL FOOD SOUVENAID ON BRAIN METABOLITES IN MILD ALZHEIMER’S DISEASE: STUDY DESIGN AND BASELINE DATA
Anne Rijpma, MSc (1,2), Olga Meulenbroek, PhD (1,2), Marinette van der Graaf, PhD (3,4), Marieke Lansbergen, PhD (5), Anke Bongers, MSc (5), Arend Heerschap, PhD (3), Marcel Olde Rikkert, MD, PhD (1,2)
(1) Department of Geriatric Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands, (2) Alzheimer Centre Nijmegen, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands, (3) Department of Paediatrics, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands, (4) Department of Radiology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands, (5) Nutricia Advanced Medical Nutrition, Danone Research, Centre for Specialised Nutrition, Wageningen, The Netherlands

P24 PREDICTIVE VALUE OF BASELINE HIPPOCAMPAL VOLUMES AND BRAIN AMYLOID BURDEN ON ATROPHY RATES FOR PREDEMENTIA ALZHEIMER’S DISEASE SUBJECTS WITH DATA FROM STUDY CN156-018 AND ADNI-1
Luc Bracoud, MSc (1), Kenneth Marek, MD (2), Jesse Cedarbaum, MD (3), Joël Schaer, PhD (1), Susan Mendick, MPH (2), Robert Berman, MD (3), Florent Roche, MSc (1), Feng Luo, PhD (3), Wendy Hayes, DO (3), Stephen Kaplita, MSc (3), John Seibyl, MD (2), Chahin Pachai, PhD (1), Vlad Coric, MD, and (3) and the Alzheimer’s Disease Neuroimaging Initiative
(1) BioClinica, Lyon, France and Newtown, PA, USA, (2) Molecular NeuroImaging, New Haven, CT, USA, (3) Bristol Myers Squibb, Princeton, NJ, USA

P25 COMPARISON OF INTRACRANIAL VOLUME QUANTIFICATION BASED ON 2D T2* AND 3D T1-WEIGHTED MRI SEQUENCES
Joël Schaer, PhD (1), Feng Luo, PhD (2), Sylvain Gouttard, MSc (1), Jesse Cedarbaum, MD (2), Luc Bracoud, MSc (1), Vlad Coric, MD (2), Florent Roche, MSc (1), Stephen Kaplita, MSc (2), Audrey Istance, MSc (1), Wendy Hayes, DO (2), Hui-Jing Yu, PhD (1), Chahin Pachai, PhD (1), Robert Berman, MD (2)
(1) BioClinica, Lyon, France and Newtown, PA, USA, (2) Bristol Myers Squibb, Princeton, NJ, USA
POSTER PRESENTATIONS

THEME: CLINICAL TRIALS: IMAGING

P26 COMPARISON OF BOUNDARY SHIFT INTEGRAL AND TENSOR BASED MORPHOMETRY TO ASSESS VOLUME CHANGES ON WHOLE BRAIN AND LATERAL VENTRICLES – APPLICATION TO STUDY CN156-018
Audrey Istace, MSc (1), Vlad Coric, MD (2), Florent Roche, MSc (1), Stephen Kaplita, MSc (2), Joël Schaerer, PhD (1), Feng Luo, MD (2), Sylvain Gouttard, MSc (1), Jesse Cedarbaum, MD (2), Luc Bracoud, MSc (1), Wendy Hayes, DO (2), Boubakeur Belaroussi, PhD (1), Hui-Jing Yu, PhD (1), Chahin Pachai, PhD (1), Robert Berman, MD (2)
(1) BioClinica, Lyon, France and Newtown, PA, USA, (2) Bristol Myers Squibb, Princeton, NJ, USA

P27 LONGITUDINAL VOLUMETRIC CHANGES IN STUDY CN156-018, AS COMPARED TO ADNI-1
Luc Bracoud, MSc (1), Robert Berman, MD (2), Florent Roche, MSc (1), Vlad Coric, MD (2), Sylvain Gouttard, MSc (1), Feng Luo, PhD (2), Joël Schaerer, PhD (1), Wendy Hayes, DO (2), Audrey Istace, MSc (1), Stephen Kaplita, MSc (2), Boubakeur Belaroussi, PhD (1), Hui-Jing Yu, PhD (1), Chahin Pachai, PhD (1), Jesse Cedarbaum, MD (2) and the Alzheimer’s Disease Neuroimaging Initiative
(1) BioClinica, Lyon, France and Newtown, PA, USA, (2) Bristol Myers Squibb, Princeton, NJ, USA

P28 THE IMPACT OF THE WHITE MATTER HYPERINTENSITIES TO THE COGNITIVE FUNCTION IN THE PATIENTS WITH BEHAVIORAL VARIANT FRONTALTEMPORAL DEMENTIA
Bon D. Ku (1), Key Hyung Park (2), Hyun Jung Han (1), Young Chul Youn (3), Bora Youn (4), Kyung Won Park (5), Jae-Hong Lee (6), Eun-Joo Kim (7), Duk L. Na (8), Key Chung Park (9)
(1) Department of Neurology, Myongji Hospital, Kwandong University College of Medicine, Gyeonggi, Korea, (2) Department of Neurology, Gachon University Gil Hospital, Incheon, Korea, (3) Department of Neurology, Chung-Ang University Hospital, Chung-Ang University College of Medicine, Seoul, Korea, (4) Department of Neurology, Kyung Hee University College of Medicine, Kyung Hee University College of Medicine, Daejeon, Korea, (5) Department of Neurology, Dong A University Medical Center, Dong A University College of Medicine, Busan, Korea*, (6) Department of Neurology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea, (7) Department of Neurology, Pusan National University Hospital, Pusan National University School of Medicine and Medical Research Institute, Busan, Korea, (8) Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, (9) Department of Neurology, KyungHee University School of Medicine, Seoul, Korea, Seoul, Korea

P29 PROPOSITION OF T1-AXIAL VISUAL RATING SCALE FOR MEDIAL TEMPORAL ATROPHY FOR CLINICAL TRIALS OF ALZHEIMER’S DISEASE
Geon Ha Kim, MD (1), Jong Won Kim, MD (2), Kyoung-Gyu Choi, MD, PhD (1), Jong-Min Lee, PhD (3), Duk L. Na, MD, PhD (4), Jee-Hyang Jeong, MD, PhD (1)
(1) Department of Neurology, Ewha Womans University Mokdong Hospital, Ewha Womans University School of Medicine, Seoul, Republic of Korea, (2) Department of Emergency Medicine, Konkuk University Medical Center, Seoul, Republic of Korea, (3) Department of Biomedical Engineering, Hanyang University, Seoul, Republic of Korea, (4) Department of Neurology, Sungkyunkwan University School of Medicine, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea

P30 AMYLOID PET SCREENING FOR ENROLLMENT INTO AD CLINICAL TRIALS: AN EFFECTIVE ENRICHMENT STRATEGY IN A PHASE 1B CLINICAL TRIAL
Jerome Barakos (1,2), Derk Purcell (1,2,3), Gregory Klein (1), Joyce Suhy (1), Joonmi Oh (1), Ping Chiao (4), Jeff Sevigny (4)
(1) Synarc Inc, Newark, CA, USA, (2) California Pacific Medical Center, San Francisco, CA, USA, (3) UC San Francisco, San Francisco, CA, USA, (4) Biogen Idec, Cambridge, MA, USA

P31 AMYLOID AND APOE4 INTERACT TO INFLUENCE COGNITIVE DECLINE OVER A SHORT FOLLOW UP PERIOD IN AGING
Elizabeth C. Mormino, PhD (1), Rebecca A. Betensky, PhD (2), Trey Hedden, PhD (3,4), Aaron P. Schultz, PhD (1,3,5), Andrew Ward, BA (5,6), Willem Huijbbers, PhD (6), Dorene M. Rentz, PsyD (1,6), Keith A. Johnson, MD (1,3,6,7), Reisa A. Sperling, MD (1,3,6); the Alzheimer’s Disease Neuroimaging Initiative*; the Australian Imaging Biomarkers and Lifestyle flagship study of ageing**; and the Harvard Aging Brain Study***
(1) Department of Neurology, Massachusetts General Hospital, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, (2) Department of Biostatistics, Harvard School of Public Health, Boston, Massachusetts 02115, (3) Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, (4) Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Charlestown, Massachusetts 02129, (5) Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, (6) Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, MA, USA, (7) Division of Nuclear Medicine and Molecular Imaging, Department of Radiology Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
POSTER PRESENTATIONS

THEME: CLINICAL TRIALS BIOMARKERS

P32  MINIMALLY-INVASIVE DETECTION OF ALZHEIMER DISEASE USING 12 MICRORNAS
Cord Stähler (1), Petra Leidinger (2), Christina Backes (2), Karen Frese (3), Jan Haas (3), Klemens Ruprecht (4), Benjamin Meder (3), Eckart Meese (2), Andreas Keller (5)
(1) Siemens Healthcare, Strategy, Erlangen, Germany, (2) Department of Human Genetics, Saarland University, Homburg-Germany, (3) Internal Medicine II, Heidelberg University, Heidelberg, Germany, (4) Clinical and Experimental Multiple Sclerosis Research Center, Charité University Medicine Berlin, Berlin, Germany, (5) Chair for Clinical Bioinformatics, Saarland University, University Hospital, Saarbrücken, Germany

P33  TIBET-MEDICINE (RATANASAMPIL INVOLVED IN PRODUCTION AND METABOLISM OF BETA-AMYLOID IN PATIENTS WITH MILD TO MODERATE ALZHEIMER'S DISEASE AT HIGH ALTITUDE
ZHU Ai-qin, ZHONG Xing, LI Gou-feng, LI Ying-lan, Liao Bao-xia, Peng Hai, CHU Yi-de
Institute of Geriatrics, Qinghai Provincial Hospital, Xining, China

P34  HYPOCRETIN AND B-AMYLOID PEPTIDE INTERACTIONS IN ALZHEIMER'S DISEASE AND NARCOLEPSY
Yves DAUVILLIERS MD, PhD (1,2,3), Sylvain LEHMANN MD, PhD (4), Isabelle JAUSSENT PhD (1,2), Jacques TOUCHON, MD (2,3), Audrey GABELLE MD, PhD (3,4)
(1) Sleep Unit, National Reference Network for Orphan Diseases (Narcolepsy, Hypersomnia, Kleine-Levin Syndrome), Department of Neurology, Gui de Chauliac Hospital, CHU Montpellier, France, (2) INSERM, U1061, Montpellier, Montpellier 1 University, France, (3) Clinical Research Memory Center Languedoc-Roussillon, Gui de Chauliac Hospital, CHU de Montpellier, France, (4) Biochimie-Protéomique Clinique – IRB – CCBHM -Inserm U1040 CHU Montpellier ; France

P35  PLASMA B-AMYLOID 40 LEVELS ARE POSITIVELY ASSOCIATED WITH MORTALITY RISKS IN ELDERLY POPULATIONS: A POPULATION-BASED PROSPECTIVE STUDY
Audrey Gabelle, Susanna Schraen, Laure-Anne Gutierrez, Cecile Pays, Olivier Rouaud, Luc Buée, Jacques Touchon, Catherine Helmer, Jean-Charles Lambert, Claudine Berr
From the Centre Mémoire Ressources Recherche Languedoc-Roussillon, CHRU Gui de Chauliac Hospital, Department of Neurology, Montpellier, France (A.G, C.P, C.B, J.T), INSERM U1061, Hôpital La Colombière, Montpellier, France (L.A.G., C.P, J.T, C.B.) and University Montpellier 1, Montpellier, France (A.G, J.T) ; From INSERM U744, Lille, France, and Institut Pasteur de Lille, Lille, France and Université de Lille Nord de France, Lille, France, and CHRU de Lille, Lille, France and INSERM U837, Lille, France (S.S, L.B, J.C.L); From INSERM 987, ISPED, Victor Segalen University, Bordeaux, France (C.H); From Centre Mémoire Ressources Recherche, CHRU Dijon, Department of Neurology, Dijon, France (O.R)

P36  IMPACT OF THE FRENCH “NATIONAL PLAN FOR ALZHEIMER 2008-2012” ON THE USE OF CSF BIOMARKERS: THE PLM STUDY
Audrey Gabelle (1,2), Julien Dumurgier (3), Olivier Vercruyssye (4), Claire Paquet (3,5), Stéphanie Bombois (4), Jean-Louis Laplanche (6), KatellPecoech (6), Susanna Schraen (7), Luc Buée (7), Florence Pasquier (4), Jacques Hugon (3,5), Jacques Touchon (1,8), Sylvain Lehmann (2)
(1) Centre Mémoire Ressources Recherche Languedoc-Roussillon, CHRU Gui de Chauliac Hospital, Department of Neurology, Montpellier, France (A.G, C.P, C.B, J.T), INSERM U1061, Hôpital La Colombière, Montpellier, France (L.A.G., C.P, J.T, C.B.) and University Montpellier 1, Montpellier, France (A.G, J.T) ; From INSERM U744, Lille, France, and Institut Pasteur de Lille, Lille, France and Université de Lille Nord de France, Lille, France, and CHRU de Lille, Lille, France and INSERM U837, Lille, France (S.S, L.B, J.C.L); From INSERM 987, ISPED, Victor Segalen University, Bordeaux, France (C.H); From Centre Mémoire Ressources Recherche, CHRU Dijon, Department of Neurology, Dijon, France (O.R)

P37  IMMUNIZATION AGAINST AΒ40 INDUCES AN INCREASE OF AΒ40 PLASMA LEVELS WHEREAS LEVELS OF AΒ42 REMAINED UNCHANGED
María Izco, Ana Mª Lacosta, María Montañés, Virginia Pérez-Grijalba, Pedro Pesini, Manuel Sarasas
Aracon Biotech Ltd. Zaragoza, Spain

P38  THE EFFECTS OF AZD1446 (A NEURONAL NICOTINIC RECEPTOR AGONIST) ON QUANTIFIED ELECTROENCEPHALOGRAPHY (QEEG) IN PATIENTS WITH MILD-TO-MODERATE ALZHEIMER’S DISEASE. QUANTITATIVE MEASUREMENTS USING A QEEG CHOLINERGIC INDEX
Kristinn Johnsens, PhD (1), Niclas Brynne, PhD (1,2), Peter Annas, PhD (2), Kristin Hannesdottir, PhD (3), Robert Alexander, MD, PhD (3), Márta Segerdahl, MD, PhD (2,4)
POSTER PRESENTATIONS

THEME: CLINICAL TRIALS BIOMARKERS

P39 PHARMACOLOGICAL REVERSAL OF AZD1446 AND DONEPEZIL AFTER SCOPOLAMINE INJECTIONS TO HEALTHY VOLUNTEERS. QUANTITATIVE MEASUREMENTS USING A QEEG CHOLINERGIC INDEX
Kristinn Johnsen, PhD (1), Niclas Brynne, PhD (1,2), Peter Annas, PhD (2), Kristin Hannesdottir, PhD (2), Robert Alexander, MD, PhD (2), Marta Segerdahl, MD, PhD (2,3)

P40 EXPERIMENTAL DESIGN, CALIBRATION, AND STATISTICAL ANALYSIS OF BLOOD PLASMA BIOASSAYS
Michael C Donohue, PhD (1,2), Robert A Rissman PhD (2,3), Chung-Kai Sun MS (2), Steve D Edland, PhD (1,3), Paul S Aisen, MD (2,3)
(1) Division of Biostatistics & Bioinformatics, Department of Family & Preventive Medicine, (2) Alzheimer’s Disease Cooperative Study, (3) Department of Neurosciences - University of California San Diego

P41 OLFATORY IDENTIFICATION DEFICITS PREDICT RESPONSE TO CHOLINESTERASE INHIBITORS IN PATIENTS WITH MILD COGNITIVE IMPAIRMENT
P. Devanand, M.D. (1), Gregory H. Pelton, M.D.(1), Howard Andrews, Ph.D. (1), Bruce Levin, Ph.D. (2)
(1) Department of Psychiatry, Columbia University, (2) Department of Biostatistics, Mailman School of Public Health, Columbia University

P42 A NOVEL GLYCAN BIOMARKER IN ALZHEIMER DISEASE
Sophia Schedin-Weiss, PhD (1), Qiushi Chen, PhD (2), Stuart Haslam, PhD (2), Anne Dell (2), Bengt Winblad, MD, PhD (1), Lars Tjernberg, PhD (1)
(1) Ki-Alzheimer Disease Research Center (Ki-ADRC), Karolinska Institutet, Department of Neurobiology, Care Sciences and Society (NVS), Stockholm, Sweden, (2) Department of Life Sciences, Imperial College, London

P43 PLASMA BIOMARKERS ASSOCIATED WITH THE APOLIPROTEIN E (APOE) GENOTYPE AND AMYLOID-BETA IMAGING
Sophie Sokolow, PhD (1,2), Kristy S Hwang, BS (3,4), Edmond Teng, MD, PhD (3,5), Andreas Lazaris (6), Paul M. Thompson, PhD (3,4,7), Clifford R.Jack, Jr., MD (8), Leslie M. Shaw, PhD (9), John Q. Trojanowski, MD, PhD (10), Holly D. Soares, PhD (11), Michael W. Weiner, MD (12,13), Liana G. ApostolovaMD (3,4)
(1) School of Nursing, University of California at Los Angeles, CA, USA, (2) Brain Research Institute, University of California at Los Angeles, CA, USA, (3) Department of Neurology, University of California Los Angeles, Los Angeles, CA, USA, (4) Imaging Genetics Center, Laboratory of Neuro Imaging, David Geffen School of Medicine, UCLA, Los Angeles, CA, USA, (5)Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, CA, USA, (6) Helen Wills Neuroscience Institute, University of California at Berkeley, Berkeley, CA, USA, (7) Department of Psychiatry and Biobehavioral Sciences,Semel Institute, David Geffen School of Medicine, University of California at Los Angeles, CA, USA, (8) Department of Diagnostic Radiology, Mayo Clinic, Rochester, MN, USA, (9) Department of Cancer Biology, Medical school of University of Massachusetts, Worcester, MA, USA, (10)Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA, USA, (11) Bristol-Meyers Squibb, Wallingford CT, USA, (12) Departments of Medicine, Radiology, and Psychiatry, University of California at San Francisco, San Francisco, CA, USA, (13) Veterans Affairs Medical Center, San Francisco, CA

P44 NEW MODELING METHOD FOR ESTIMATION OF ENTIRE CHRONOLOGICAL CHANGES OF MULTIPLE BIOMARKERS FROM FRAGMENTED INFORMATION
Takaaki Ishida, MS (1), Akihiro Hisaka, PhD (2), Masashi Honma, MS (1), Kazutoshi Yokozuka, MS (3), Hidefumi Kasai, MS (3), Takashi Moritoyo, MD, PhD (4), Yoshihiro Arakawa, PhD (5), Takeshi Iwatsubo, MD, PhD (6), Hiroshi Suzuki, PhD (1)
(1) Department of Pharmacy, The University of Tokyo Hospital, Tokyo, Japan, (2) Pharmacology and Pharmacokinetics, The University of Tokyo Hospital, Tokyo, Japan, (3) Bell Medical Solutions Inc. Tokyo, Japan, (4) Unit for Early and Exploratory Clinical Department, The University of Tokyo Hospital, Tokyo, Japan, (5) Clinical Research Support Center, The University of Tokyo Hospital, Tokyo, Japan, (6) Neuroscience, Faculty of Medicine, The University of Tokyo, Tokyo, Japan

THEME: CLINICAL TRIALS: COGNITIVE ENDPOINTS

P45 ANALYSIS OF LEXIS IN SPONTANEOUS CONVERSATION WITH ALZHEIMER’S DISEASE PATIENTS
Renée Alegria, PhD (1,2), Cleide Rosana Prisco (3), Cassio MC Bottino (2), MD, PhD, Maria Inês Nogueira, PhD (1)
(1) Neuroscience and Behavior, Institute of Psychology, University of São Paulo, SP, Brazil, (2) PROTER- Old Age Research Group, Institute of Psychiatry, School of Medicine, University of Sao Paulo, SP, Brazil, (3) Institute of Biomedical Sciences, University of Sao Paulo, SP, Brazil

P46 CREATING A COMPOSITE SCORE : METHODOLOGY COMPARISON
Noel Ellison, MS, Suzanne Hendrix, PhD, Stephanie Stanworth, MS, Leah Garriott, MS
Pentara Corporation, Salt Lake City, UT - USA
P47 LONG-TERM NEUROPSYCHIATRIC SYMPTOM INTENSITY IN ALZHEIMER’S DISEASE IS PREDICTABLE VIA SHORT-TERM SYMPTOM SEVERITY AS MEASURED BY SYMPTOMGUIDE™ SCORE
Kenneth Rockwood, MD, PhD (1,2), Arnold Minitski, PhD (1,2), Matthew Richard, BSc (1), Matthias Kurth, MD, PhD (3), J Patrick Kesslak, PhD (3), Susan Abushakra, MD (3)
(1) DGI Clinical Inc., Halifax, NS, Canada, (2) Division of Geriatric Medicine, Dalhousie University, Halifax, NS, Canada, (3) Eli Lilly Pharmaceuticals, San Francisco, CA USA

P48 MODELING OF ADAS-COG PLACEBO RESPONSE IN ASIAN AND CAUCASIAN PATIENTS WITH ALZHEIMER’S DISEASE
An Hye Kim, MD (1), Kyoungsoo Lim, MD, PhD (1), Jae Yong Chung, MD, PhD (2)
(1) Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seongnam, Korea, (2) Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Bundang Hospital, Seongnam, Korea

P49 LONG-TERM EFFECT OF CURRENT ALZHEIMER’S MEDICATIONS ON COGNITIVE FUNCTION AMONG CHINESE ALZHEIMER’S DISEASE PATIENTS: A THREE YEAR PROSPECTIVE STUDY
Chu LW (1), Kwan F (1), Yik PY (1), Song YQ (2)
(1) Division of Geriatric Medicine, Department of Medicine, Queen Mary Hospital, The University of Hong Kong, (2) Department of Biochemistry, The University of Hong Kong

P50 EFFICIENT SCREENING FOR MILD COGNITIVE IMPAIRMENT DUE TO AD FOR CLINICAL TRIAL ENROLLMENT
Stephen W. Hurt, PhD (1), Bruce Albala, PhD (2), Paul Maruff, PhD (3)
(1) Psychiatry Department, Weill Cornell Medical College, White Plains, New York USA, (2) Eisai Inc., Woodcliff Lake, New Jersey, USA, (3) CogState, New Haven, Connecticut, USA

P51 THE GOTHENBURG MCI STUDY: THE NEUROPSYCHOLOGICAL PROFILES OF INCIPIENT AD AND VASCULAR COGNITIVE DISORDER DIFFER
Arto Nordlund, PhD, Maria Bjerke, PhD, Mattias Göthlin, MSc, Carl Eckerström, MD, PhD, Anders Wallin, MD, PhD
Institute of Neuroscience and Physiology, Sahlgrenska Academy at University of Gothenburg, Molndal, Sweden

P52 EFFECTS OF BIOMARKERS ON COGNITIVE DOMAINS IN ALZHEIMER’S DISEASE
Opler M (1,3), Yavorsky C (1,2), Rothman B (1), Lucic L (1,4), Khan A (1,5)
(1) ProPhase, LLC, (2) CROnos CCS, (3) New York University School of Medicine, (4) Pratt Institute, (5) Nathan S. Kline Institute for Psychiatric Research

P53 DIFFERENTIAL ITEM FUNCTIONING AND THE ALZHEIMER’S DISEASE ASSESSMENT SCALE-COGNITIVE (ADAS-COG) AMONG PATIENTS WITH ALZHEIMER’S DISEASE
Yavorsky C (1,2), Khan A (1,5), Opler M (1,3), Lucic L (1,4), Rothman B (1)
(1) ProPhase, LLC, (2) CROnos CCS, (3) New York University School of Medicine, (4) Pratt Institute, (5) Nathan S. Kline Institute for Psychiatric Research

P54 ALTERATIONS IN VASCULAR FUNCTION IN ALZHEIMER’S DISEASE AND ACROSS THE ADULT LIFESPAN
Sarah Catchlove, PhDc, Andrew Pipingas, PhD, Helen Macpherson, PhD
Centre for Human Psychopharmacology, Swinburne University of Technology, Hawthorn, VIC, Australia

P55 LIVING ALONE IN ALZHEIMER’S DISEASE—THE INFLUENCE OF FUNCTIONAL IMPAIRMENT
Carina Wattmo, RN, BSc, PhD, Lennart Minthon, MD, PhD, Åsa K. Wallin, MD, PhD
Clinical Memory Research Unit, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden

P56 CANCELLED
POSTER PRESENTATIONS

THEME: EPIDEMIOLOGY AND CLINICAL TRIALS

P57  CHARACTERISTICS OF PATIENTS RECENTLY DIAGNOSED WITH ALZHEIMER’S DISEASE: A 3.5-YEAR TIME-COURSE ANALYSIS
Kasem Akhras (1), Baoguo Jiang (1), Beenaish S. Manzoor (2),  Shawn Yu (1), Jiao Yang (1)
(1) Takeda Pharmaceuticals International, Inc., Deerfield, IL, USA, (2) University of Illinois at Chicago, College of Pharmacy, Chicago, IL, USA

P58  SHARING DATA FROM ONGOING TRIALS TO BETTER DESIGN NEW AD PREVENTION TRIALS: THE HEALTHY AGING THROUGH INTERNET COUNSELING IN THE ELDERLY (HATICE) PROJECT
Sandrine Andrieu (1,2,3,4), Nicola Coley (1,2,4), Miaa Kivipelto (5,6,7), Francesca Mangialasche (5), Tiia Ngandu (7), Yannick Meiller (8), Juliette Guillermont (1,2,8), Abraham van de Groep (9), Eric P. Moli van Charante (10), Carol Brayne (11), Hilkka Soininen (6,12), Willem A van Gool (13), Edo Richard (13) for the HATICE consortium

THEME: ANIMAL MODELS AND CLINICAL TRIALS

P59  HYPERTHERMIA EXACERBATES AMYLOID-BETA PEPTIDE INFUSION INDUCED ALZHEIMER’S DISEASE PATHOLOGY AND BEHAVIORAL DISTURBANCES
Aruna Sharma, MD (1), Dafin F Muresanu, MD, PhD (2), Rudy J Castellani, MD, Ph D (3), Mark A Smith, MD, Ph D (4), Hari S Sharma, MD, Ph D, Dr Med Sci (5)
(1) Surgical Sciences, Anesthesiology & Intensive Care Medicine, Uppsala University Hospital, Sweden, (2) Dept. Clinical Neurosciences, University of Medicine & Pharmacy, Cluj-Napoca, Romania, (3) University of Maryland, Dept. of Pathology, Baltimore, MD, USA, (4) Case Western Reserve Medical University, Dept. of Pathology, Cleveland, OH, USA, (5) Dept. Surg Sciences, Anesthesiology & Intensive Care medicine, University Hospital, Uppsala University, Uppsala, Sweden

P60  5-LIPOXYGENASE PHARMACOLOGICAL BLOCKADE DECREASES TAU PHOSPHORYLATION IN VIVO: INVOLVEMENT OF THE CYCLIN-DEPENDENT KINASE-5
Jin Chu, Domenico Pratico
Temple University, Philadelphia PA, USA

P61  EFFECTS OF ELND005 (SCYLLO-INOSITOL) AND CLOZAPINE ON SOCIAL WITHDRAWAL BEHAVIORS: DIFFERENTIAL PROFILES IN A PCP ANIMAL MODEL
Paul Shughrue, PhD (1), Allison Whalen (1), Kevin Quinn, PhD (2), Susan Abushakra, MD (2), Gene Kinney, PhD (1)
(1) Prothena Biosciences, South San Francisco, CA, USA, (2) Elan Pharmaceuticals, San Francisco, CA USA

P62  EARLY GLUTAMATERGIC DYSFUNCTION IN A MOUSE MODEL OF FAMILIAL ALZHEIMER’S DISEASE
Jinghua Jin (1), Sanh H. Luu (1), Kelly Tseng (1), Karen Gylys (1,2), Sophie Sokolow (1,2,3)
(1) UCLA School of Nursing, (2) UCLA Brain Research Institute, (3) UCLA Clinical and Translational Science Institute, Los Angeles, CA, USA

P63  APP DOSAGE CAUSES SLEEP DISTURBANCES IN A GENETIC MODEL OF DOWN SYNDROME
Damien Colas, PhD (1), Chulun Bayarsaikhan, MD, PhD (1), Hagiwara Grace (1), Mobley William, MD, PhD (2), Heller HC, PhD (1)
(1) Department of Biology, Stanford University, Stanford, CA, USA, (2) Department of Neurosciences, UCSD, San Diego, CA, USA

P64  POTENTIAL ROLE OF OREXIN IN THE PATHOGENESIS OF ALZHEIMER’S DISEASE
Jee Hoon ROH (1,2), Ashish HEDA (2), Mary Beth FINN (2), Tom MAHAN (2), Mingjie Li (2), Seiji NISHINO (3), Luis DE LECEA (3), Masashi YANAGISAWA (4), David HOLTZMAN (2)
(1) Department of Neurology, Asan Medical Center, Seoul, Korea, (2) Department of Neurology, Washington University School of Medicine, MO, USA, (3) Psychiatry and Behavioral Sciences, Stanford University, CA, USA, (4) Molecular Genetics, UT Southwestern, TX, USA
POSTER PRESENTATIONS

THEME: NEW THERAPIES AND CLINICAL TRIALS

P65  EFFECTS OF TREATMENT WITH SOLANEZUMAB IN PATIENTS WITH ALZHEIMER’S DISEASE WHO RECEIVE CURRENT STANDARD OF CARE
Vicki Poole Hoffmann, PharmD, Michael Case, MSc, Ann Marie Hake, MD
Neuroscience, Eli Lilly and Company, Indianapolis, IN, USA

P66  THE INTEGRATIVE TREATMENT IN THE CONTEXT OF THE PRESERVATION OF THE COGNITIVE PERFORMANCE IN ALZHEIMER PATIENTS
Gjumrakch Aliev, MD, PhD (1,2), Ilya Bragin, MD (3), Valentin Bragin, MD, PhD (4)
(1) GALLY International Biomedical Research Consulting LLC., San Antonio, Texas, USA, (2) School of Health Science and Healthcare Administration, University of Atlanta, GA, USA, (3) Upstate Medical University, New York, NY, USA, (4) Stress Relief and Memory Training Center,Brooklyn, NY, USA

P67  APPLICATION OF TAI CHI 6-FORM SPORT APPARATUS IN PATIENTS WITH ALZHEIMER’S DISEASE
Alice M.K. Wong MD (1,2), Yu-Ting Chiu MS (1), Chia-Wei Wang PT MS (1), Yu-Cheng Pei MD PhD (1,2), Wen-Chuin Hsu MD PhD (3)
(1) Department of Rehabilitation Medicine & Neurology, Chang Gung Memorial Hospital, Taoyuan, Taiwan, (2) Healthy Aging Research Center, Chang Gung University, Taoyuan, Taiwan, (3) Chang Gung Dementia Center, Chang Gung Memorial Hospital, Taoyuan, Taiwan

P68  HUMAN PHOTOSYNTHESIS AND ALZHEIMER’S DISEASE
Arturo Solís Herrera, MD, PhD
Human Photosynthesis Study Center, Aguascalientes, Mexico

P69  DIABETES EXACERBATES ALZHEIMER’S DISEASE INDUCED BRAIN PATHOLOGY. POSSIBLE NEUROPROTECTIVE EFFECTS OF CEREBROLYSIN
Hari S Sharma (1), Dafin F. Muresanu (2), Rudy J Castellani (3), Mark A Smith (4), Ranjana Patnaik (5), Herbert Mössler (6), Aruna Sharma (1)
(1) Cerebrovascular Research Laboratory, Department of Surgical Medicine, Anesthesiology & Intensive Care Medicine, University Hospital, Uppsala University, Uppsala, Sweden, (2) Department of Pathology, University of Maryland, Baltimore, MD, USA, (3) Dept. of Clinical Neurosciences, University Hospital, University of Medicine & Pharmacy, Cluj-Napoca, Romania, (4) Department of Pathology, Case Western Reserve University, Wolstein Research Building, Room 5125, 2103 Cornell Road, Cleveland, Ohio 44106 USA, (5) Department of Biomaterials, School of Biomedical Engineering, National Institute of Technology, Banaras Hindu University, Varanasi-221005, India, (6) Ever NeuroPharma, Unterach, Austria

P70  THE USE OF HIGH CONTENT CELLULAR ANALYSIS TO IDENTIFY KENPAULLONE AS AN EFFECTIVE COMPOUND IN DIRECTING NEURAL STEM CELL DIFFERENTIATION
Xiangjian Luo, PhD, Zheng Yin, Dongbing Gao, Xiaofeng Xia, Stephen TC Wong
Department Systems Medicine and Bioengineering, The Methodist Hospital Research Institute, Houston, TX - USA

P71  MULTILEVEL EVALUATION OF AN ANDEAN SHILAJIT BASED COMPOUND
Gonzalo A. Farias, MD, PhD (1,2), Leonardo Guzmán (1), George Perry, PhD (3), Ricardo B. Maccioni, PhD (1)
(1) International Center for Biomedicine (ICC), Avda.Vitacura 2568, Vitacura, Santiago, Chile, (2) Department of Neurology and Neurosurgery, Faculty of Medicine, Universidad de Chile, Santiago, Chile, (3) College of Sciences, University of Texas, San Antonio, TX, USA

P72  IMPACT OF PRESENLIN/GAMMA-SECRETASE DEGRADATION OF EXTRACELLULAR AB42
Naoki Mizuta, MD, Masayasu Okochi, MD, PhD, Shinji Tagami, MD, PhD, Kanta Yanagida, PhD, Takashi Kodama, PhD, Masatoshi Takeda, MD, PhD
Department of Psychiatry, Osaka University Graduate School of Medicine, Osaka, Japan

P73  XYLOCOSIDE G REDUCES AMYLOID-B INDUCED NEUROTOXICITY THROUGHINHIBITING NF-KB SIGNALING PATHWAY
Dehua Chui (1), Ting Zhou (1), Tao Zhang (1), Hecheng Wang (1), Yawei Tong (1), Yan Yu (1), Pengfei To (2)
(1) Neuroscience Research Institute & Department of Neurology, Third Hospital, Peking University, China, (2) The State Key Laboratory of Natural and Biomimetic Drugs, Health Science Center, Peking University, China
POSTER PRESENTATIONS

THEME: NEW THERAPIES AND CLINICAL TRIALS

P74 WHY AMYLOID THERAPY WON’T CURE ALZHEIMER’S DISEASE AND IS A WASTE OF TIME AND PUBLIC FUNDS?
Alexei Koudinov, MD, PhD, DrSci (1,2,3), Natalia Shishkova, MD, PhD, DrSci (1,2), Temirbolat Berezov, MD, PhD, DrSci (1,2)
(1) Biochemistry, TT Berezov Laboratory, Russian People Friendship University, (2) Orekhovich Institute of Biomedical Chemistry, Moscow, Russia, (3) Neurobiology of Lipids, Rehovot, Israel

P75 FYN KINASE INHIBITION BY SARACATINIB FOR THE TREATMENT OF ALZHEIMER’S DISEASE: RATIONALE, PRECLINICAL SUPPORT AND PHASE 1B TRIAL DESIGN
Haakon B. Nygaard, MD, PhD (1,2), Ji Won Um, PhD (1), Adam C. Kaufman, BS (1), Christopher van Dyck, MD (3), Stephen M. Strittmatter, MD, PhD (1,2)
(1) Cellular Neuroscience, Neurodegeneration and Repair Program(CNNR), Yale University, New Haven, CT, USA, (2) Department of Neurology, Yale University, New Haven, CT, USA, (3) Department of Psychiatry, Yale University, New Haven, CT, USA

P76 AN OBSERVATIONAL STUDY IN OUTPATIENTS AND NURSING HOME RESIDENTS WITH ALZHEIMER’S DISEASE TREATED WITH ORAL OR TRANSDERMAL MONOTHERAPY TO EVALUATE COMPLIANCE, TREATMENT OUTCOME AND CAREGIVER SATISFACTION
Mathieu Ceccaldi, MD, PhD (1), Pierre Jouanny, MD (2), Olivier Guerin, MD (3), Alain Bredin, MD (4), Jean Jacques Pere, MD (5), Isabelle Bourdeix, PhD (5)
(1) CHU Timone, Marseilles, France, (2) CHU Amiens, France, (3) CHU Nice, France, (4) Biaye, France, (5) Novartis Pharma Rueil-Malmaison France
General Information

Congress Venue
Westin Gaslamp Quarter
910 Broadway Circle
San Diego, California 92101

Welcome Reception
Thursday, November 14
Hosted by the Alzheimer’s Disease Cooperative Study (ADCS) at the University of California San Diego, CtaD 2013 welcomes you to an evening of networking and relaxation at the Omni Hotel San Diego where from its Palm Terrace you will take in the extraordinary views of the San Diego Bay, the downtown skyline and the Gaslamp Quarter.

Buses will depart at 6:30 pm from the Westin Gaslamp and return attendees directly to the hotel afterwards.

Omni San Diego Hotel
675 L Street
San Diego, California 92101

Practical details:
Registration desk opening hours:
• Thursday, November 14th
  7:00 am - 6 pm
• Friday, November 15th
  7:30 am - 5:30 pm
• Saturday, November 16th
  7:30 am - 12:30 pm

CME credits:
Please come see us at the Management desk to obtain your CME certificate. Remember to fill out the overall evaluation and daily evaluations (both in your attendee bag) to obtain your certificate in order to abide by CME guidelines.

OUR LOCAL PARTNER
The Alzheimer’s Disease Cooperative Study (ADCS) was formed in 1991 as a cooperative agreement between the National Institute on Aging (NIA) and the University of California, San Diego. The ADCS is a major initiative for Alzheimer’s disease (AD) clinical studies in the Federal government, addressing treatments for both cognitive and behavioral symptoms. This is part of the NIA Division of Neuroscience’s effort to facilitate the discovery, development and testing of new drugs for the treatment of AD and also is part of the Alzheimer’s Disease Prevention Initiative.

More at www.adcs.org
Continuing Medical Education

This UCSD School of Medicine accreditation and its designated number of CME credits are recognized by all the national authorities of the countries of the European Union. Individual physicians are awarded the designated number of corresponding European credits by the European Accreditation Council for Continuing Medical Education EACCME.

In order to claim your credits for this event, please fill out the overall and daily evaluations in your attendee bags. Certificates will be available at the Conference Management desk at the end of the event.

Course Description

Alzheimer’s disease is one of the most important health challenges facing aging populations worldwide. The development of the next generation of Alzheimer’s disease drugs is becoming essential to face up to this challenge. New pathways have been identified with biomarkers, facilitating novel trial designs for studies of tau-based therapies and other disease-modifying drugs including immunotherapy. However, methodological challenges continue to slow the development of specific new drug candidates. One of the objectives of the conference is to identify these hurdles and find ways to address them by bringing together world leaders in AD drug development to discuss solutions to the difficulties that have slowed the pace of progress, with a particular focus on clinical trial methodology.

Target Audience

The target audience for CtaD2013 includes neurologists, psychiatrists and other clinicians and scientists involved in geriatric care, research, imaging and drug development for patients with Alzheimer’s disease and other neurodegenerative disorders. Other healthcare professionals who may benefit from this activity are clinical research coordinators, nurses, speech therapists and other AD and dementia occupational therapists, psychologists and neuropsychologists.

CTAD 2013: Learning objectives

During this event essential learning objectives will be covered so that at the end of the conference each participant should be able to:

1. Translate the significance to the drug development process of each individual phase of clinical trials from Phase I to Phase IV.
3. Interpret back outcomes of APOE4-related therapeutic strategies.
4. Identify and evaluate interdisciplinary approaches combining biochemistry, molecular and cell biology, and transgenic modeling to unveil AD molecular mechanisms.
5. Describe new drug combination therapies under study and their future applications in the field of AD.
6. Implement in research studies: cognitive, clinical and biomarker measures that characterize the progression through the asymptomatic, prodromal and dementia phases of AD.
7. Interpret back valuable information on new upcoming molecules in order to educate fellow physicians and propose alternatives to patients.
8. List the novel methodologies or biomarkers essential in identifying predementia patients most at risk of developing AD.
9. List study findings, including safety, biomarker and clinical findings, presented at the conference underlying progress in understanding the amyloid hypothesis.
10. Describe new composite outcome scores that optimize the power for measuring clinical disease progression for trials in a MCI and pre-MCI populations.
11. Describe and interpret sensitive biochemical (e.g. CSF A-beta, tau and phospho tau levels) and neurophysiological (e.g. QEEG, ERP) biomarkers of early AD detection.
12. Interpret ERP data in AD clinical trials and drug development for cohort selection and monitoring disease progression.
13. Identify and evaluate new methods for optimally scoring each patient’s test item responses and overall test performance, for determining the number of dimensions underlying the test’s performance, and for adjusting for sample bias effects.
14. Interpret back AD impact in other populations like Down Syndrome.
15. Express appreciation for vertical integration and the impact it can have by improving knowledge transfer and drug development.

Needs Assessment
CTAD 2013 Scientific committee identified several practice gaps in designing and conducting AD Clinical Trials and developed the program to address these gaps, namely:
• The need to appreciate the full spectrum of AD from an asymptomatic stage through dementia
• The need for learning how dementia can affect specific population subgroups
• The need to elucidate risk factors for AD and other dementias
• The need to identify and avoid methodological errors in the design of multicenter and international clinical trials
• The need for improved measurement of cognitive deficits
• The need to keep up with scientific advances regarding biomarkers of AD pathologies.

Beyond these global practice gaps addressed throughout the conference other essential learning objectives will be covered so that at the end of the conference each participant will be able to understand:
• The importance of each individual phase of clinical trials from Phase I to Phase IV
• The relevance of neurotransmitters and cortical excitability in Alzheimer’s disease pathology
• The cognitive, clinical and biomarker measures that characterize the progression through the asymptomatic, prodromal and dementia phases of AD.

Accreditation statement:
The University of California, San Diego School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit designation statement:
The University of California, San Diego School of Medicine designates this live activity for a maximum of 18.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Cultural and Linguistic Competency Statement:
California Assembly Bill 1195 requires continuing medical education activities with patient care components to include curriculum in the subjects of cultural and linguistic competency. It is the intent of the bill, which went into effect on July 1, 2006, to encourage physicians and surgeons, CME providers in the state of California, and the Accreditation Council for Continuing Medical Education to meet the cultural and linguistic concerns of a diverse patient population through appropriate professional development. The planners, speakers and authors of this CME activity have been encouraged to address issues relevant in their topic area. In addition, a variety of resources are available that address cultural and linguistic competency, some of which may be included in your syllabus or handout materials. Additional resources and information about AB1195 can be found on our website at http://cme.ucsd.edu.
Faculty List

Course Directors

Paul S. Aisen, MD
Alzheimer’s Disease Cooperative Study (ADCS)
Department of Neurosciences
UCSD School of Medicine
San Diego, USA

Jacques Touchon, MD, PhD
Chair of the Department of Neurology
Montpellier University Hospital
INSERM U1061
Montpellier, France

Bruno Vellas, MD, PhD
Toulouse University Hospital
Department of Neurology
Toulouse, France

Michael Weiner, MD
University of California at San Francisco,
San Francisco, USA

UC San Diego

Colin Ard, PhD
Department of Neurosciences
UCSD School of Medicine

William Mobley, MD, PhD
Professor and Chair
Department of Neurosciences
UCSD School of Medicine

Robert Rissman, PhD
UCSD Health Sciences
Department of Neurosciences
UCSD School of Medicine

Visiting Faculty

Erin Abner, PhD
Sanders-Brown Center on Aging
University of Kentucky
Lexington, KY, USA

Susan Abushakra MD
VP Global Development
AD Program Leader
Elan Pharmaceuticals
S. San Francisco, CA, USA

Michael G. Agadjanyan, PhD
Department of Molecular Immunology
Institute for Molecular Medicine
Huntington Beach, CA, USA

Bruce Albala, PhD
Eisai Inc.
Woodcliff Lake, NJ, USA

Raymond Bartus, PhD
RTBioconsultants, Inc.
San Diego, CA, USA

Martina Bocchetta, MD
LENITEM (Laboratory of Epidemiology, Neuroimaging and Telemedicine)
IRCCS – S. Giovanni di Dio Fatebenefratelli Brescia, Italy

Randall Bateman, MD, PhD
Washington University
School of Medicine
St Louis, MO, USA

John Breitner, MD, MPH
Centre for Studies on Prevention of AD McGill University Faculty of Medicine
Montreal, Québec, Canada

Alexandre Castellano
Research Center on Aging and Department of Medicine, University of Sherbrooke Sherbrooke, Quebec, Canada

Marco Cecchi, PhD
Neuronetrix
Louisville, KY, USA

Yun-Fei Chen, PhD
Neuroscience
Eli Lilly and Company
Indianapolis, IN, USA

Jeffrey Cummings, MD
Cleveland Clinic Lou Ruvo Center for Brain Health
Las Vegas, NV, USA

Jean-François Dartigues, MD, PhD
INSERM U897
Epidemiology and Biostatistics Unit, CMRR Bordeaux-Pellegrin
Bordeaux, France

Julien Delrieu, MD
Toulouse Alzheimer’s Disease Research Clinical Center - Gérontopôle,
Toulouse, France

Bruno Dubois, MD, PhD
Department of Neurology Salpêtrière Hospital
Paris, France

Larry Ereshefsky
PharmaD PAREXEL
International Glendale, CA, USA

Milan Fiandaca, MD
Surgery Department UCLA
Los Angeles, CA, USA

Massimo S. Fiandaca, MD
Dpts of Neurology and Neuroscience
Georgetown University Medical Center
Washington, DC, USA

Audrey Gabelle, MD
Department of Neurology
University Hospital Gui de Chauliac Montpellier, France

Katherine R. Gray, PhD
IXICO Ltd
London, United Kingdom

Serge Gauthier, MD
McGill Center for Studies in Aging,
Douglas Mental Health Research Institute
Montreal, Canada

John Harrison, PhD
Polyphymnia Translational Research
Metsi Cognition, Ltd.
Dept. of Medicine, Imperial College,
London, UK

Samuel T Henderson, PhD
Neuroscience
Janssen Alzheimer Immunotherapy R&D
South San Francisco, CA - USA

Keith A. Johnson, MD
Massachusetts General Hospital
Harvard Medical School
Boston, MA, USA

Charles Kerbage, PhD
Cognobix, Inc.
Acton, MA, USA

Nzeera Ketter, MD
Janssen Alzheimer Immunotherapy R&D
South San Francisco, CA - USA

Nicholas Kozauer, MD
Food and Drug Administration,
Silver Spring, MD, USA

Robert Krikorian, PhD
Department of Psychiatry & Behavioral Neuroscience
University of Cincinnati
Academic Health Center
Cincinnati, OH, USA

Anit Lampit
Regenerative Neuroscience Group Brain and Mind
Research Institute University of Sydney
Sydney, Australia

Andreas Langer, PhD Molecular Pharmacology Unit
Swiss Federal Institute of Technology
Zurich, Switzerland

San Diego
Valérie Legrand, PharmD
ICON
Paris, France

Veronica Logovsky, MD, PhD
Eisa Inc.
Neuroscience Product Creation Unit
Woodcliff Lake, NJ, USA

Prisca Lucas, PharmD, PhD
Pfizer PGRD
Paris, France

Richard A Margolin MD
Alzheimer’s disease Neuroimaging Initiative
Janssen Alzheimer Immunotherapy LLC,
South San Francisco, CA, USA

Paul Maruff, MD
CogState Ltd
The Florey Institute of Neuroscience and Mental Health
Parkville, Victoria, Australia

Mark A. Mintun, MD
Avid Radiopharmaceuticals, Inc
Philadelphia, PA, USA

Lisa Mosconi, PhD
Assistant professor of Psychiatry
PET Imaging Research Director, Center for Brain Health
New York U School of Medicine
New York, NY, USA

Anne M. Murray, MD
Department of Medicine and Geriatrics
Hennepin County Medical Center
Minneapolis, MN USA

Omnia Nayel, MD, PhD
Pharmacology department
King Saud University
Riyadh, KSA

Joonmi Oh, MD
Synarc Inc
Newark, NJ, USA

Nobuyuki Okamura, MD, PhD
Department of Pharmacology
Tohoku University School of Medicine
Sendai, Japan

Masayasu Okochi, MD, PhD
Department of Psychiatry
Osaka University Graduate School of Medicine
Osaka, Japan

Pierre-Jean Ousset, MD
CenGeps Alzheimer Drug Trial Network,
Gerontopole
Toulouse, France

Harish C. Pant, MD
Senior Investigator, NINDS / NIH
Bethesda, MD, USA

Robert Paul, PhD
Genentech
South San Francisco, CA, USA

Pedro Pesini, PhD
Aradon Biotech Ltd.
Zaragoza, Spain

Ronald C. Petersen, MD, PhD
Mayo Alzheimer’s Disease Research Center
Mayo Clinic
Rochester, MN, USA

Anton P. Porsteinsson, MD
Department of Psychiatry
University of Rochester
Rochester, NY, USA

Eric Reiman, MD
Executive Director
Banner Alzheimer’s Institute
Phoenix, AZ, USA

Dorene M. Rentz, PsyD
Departments of Neurology, Massachusetts General Hospital and Brigham and Women’s Hospital
Boston, MA, USA

Michael T. Ropacki, PhD
Neurology Department
Loma Linda University
Janssen Research & Development, LLC,
San Francisco, CA, USA

Allen D. Roses, MD
Zinfandel Pharmaceuticals, Inc.,
Duke Bryan ADRC
Durham, NC, USA

Mark Schmidt, MD
Janssen Alzheimer Immunotherapy
Research and Development
Beerse, Antwerp, Belgium

Lon Schneider, MD
AD Research and Clinical Center
Department of Psychiatry Geriatric Studies Center
University of Southern California
Los Angeles, CA, USA

David Scott, PhD
Synarc, Inc.
Newark, CA, USA

Kohkan Shamsi MD, PhD
RadbMD
New York, NY, USA

William R. Shankle, MS MD FACP
Shankle Clinic Newport Beach, CA
Department of Cognitive Sciences,
UC Irvine, Irvine, CA, USA

Hong Liu-Seifert, PhD
Lilly Research Laboratories
Lilly Corporate Center
Indianapolis, IN, USA

Jeanne Stemmelin, PhD
Sanofi Research and Development
Chilly Mazarin, France

Duygu Tosun, PhD
Dpt of Radiology and Biomedical Imaging - UCSF
San Francisco, CA, USA

Michael Valenzuela, PhD
Regenerative Neuroscience Group Brain and Mind
Research Institute University of Sydney
Sydney, Australia

Carina Wattmo, RN, BSc, PhD
Clinical Memory Research Unit
Department of Clinical Sciences,
Lund University
Malmö, Sweden

Keith Wesnes PhD
Bracket Global
Goring on thames, UK
Swinburne University
Melbourne, Australia

Dieter Willbold, PhD
Forschungszentrum Jülich,
Jülich, Germany
Heinrich-Heine-Universität Düsseldorf
Institut für Physikalische Biologie,
Düsseldorf, Germany

Robin Wolz, PhD
IXICO Ltd
Imperial College London
London, UK

Dieter Willbold, PhD
Forschungszentrum Jülich,
Jülich, Germany
Heinrich-Heine-Universität Düsseldorf
Institut für Physikalische Biologie,
Düsseldorf, Germany

Robin Wolz, PhD
IXICO Ltd
Imperial College London
London, UK
It is the policy of the University of California, San Diego School of Medicine to ensure balance, independence, objectivity and scientific rigor. All persons involved in the selection, development and presentation of content are required to disclose any real or apparent conflicts of interest. All conflicts of interest will be resolved prior to an educational activity being delivered to learners through one of the following mechanisms 1) altering the financial relationship with the commercial interest, 2) altering the individual’s control over CME content about the products or services of the commercial interest, and/or 3) validating the activity content through independent peer review. All persons are also required to disclose any discussions of off label/unapproved uses of drugs or devices. Persons who refuse or fail to disclose are disqualified from participating in the CME activity. Participants will be asked to evaluate whether the speaker’s outside interests reflect a possible bias in the planning or presentation of the activity. This information is used to plan future activities.

<table>
<thead>
<tr>
<th>SPEAKER NAME</th>
<th>NAME OF COMMERCIAL INTEREST</th>
<th>NATURE OF RELEVANT RELATIONSHIP</th>
<th>Will refrain from making recommendations</th>
<th>Will use “best available evidence”</th>
<th>Alternative presenter</th>
<th>Divested</th>
</tr>
</thead>
<tbody>
<tr>
<td>Susan Abushakra</td>
<td>Elan Pharmaceuticals, Inc</td>
<td>Full-time employee and stock shareholder</td>
<td>x</td>
<td>x</td>
<td></td>
<td></td>
</tr>
<tr>
<td>John Alam</td>
<td>Sanofi</td>
<td>Employee</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td></td>
</tr>
<tr>
<td>Bruce Albala</td>
<td>Eisai Inc</td>
<td>I am a full-time employee of and responsible for the development and clinical program to develop the new chemical entity. As a representative of Eisai Inc I am providing funding to CogState Ltd for the computer battery and related services as part of an ongoing investigational clinical trial.</td>
<td>x</td>
<td>x</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gustavo Alva</td>
<td>Accera, Cognoptix, Merck, Novartis, TauRx, Janssen, Pfizer, Otsuka, Lundbeck and Forest Takeda</td>
<td>Grants/Research Support recipient and Speaker’s Bureau</td>
<td>x</td>
<td>x</td>
<td></td>
<td></td>
</tr>
<tr>
<td>H. Michael Arrighi</td>
<td>Janssen Alzheimer Immunotherapy</td>
<td>Employee</td>
<td>x</td>
<td>x</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mark Austin</td>
<td>Ixico</td>
<td>Employee</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clive Ballard</td>
<td>Lundbeck</td>
<td>Research funding for King’s College London and Honorary recipient</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>Raymond T. Bartus</td>
<td>Sangamo</td>
<td>Occasional consultant</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tiffany Baumann</td>
<td>Ceregene, Inc</td>
<td>Employee</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Raphael Bejuit</td>
<td>Sanofi</td>
<td>Employee</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td></td>
</tr>
<tr>
<td>Sarah Berg</td>
<td>Neuronetrix</td>
<td>Employee</td>
<td>x</td>
<td>x</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kaj Bliennow</td>
<td>Kuyowa Kirin Pharma, Pfizer, Roche</td>
<td>Advisory board</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>Stephen Brannan</td>
<td>Takeda</td>
<td>Employee</td>
<td>x</td>
<td>x</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Robert Brashear</td>
<td>Janssen AI, LLC</td>
<td>Full-time employee</td>
<td>x</td>
<td>x</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Henry Brodaty</td>
<td>Janssen, Lilly, Medivation, Sanofi, Servier Pfizer, Novartis, Janssen, Lundbeck, Nutricia Merck, Baxter, Lilly, Nutricia</td>
<td>Investigator Advisory Board</td>
<td>x</td>
<td>x</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Andrew Budson</td>
<td>Neuronetrix</td>
<td>Site PI for clinical trial of Neuronetrix device</td>
<td>x</td>
<td>x</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kumar Budur</td>
<td>Takeda</td>
<td>Employee</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Shauna Burkholder</td>
<td>Neuronetrix</td>
<td>Employee</td>
<td>x</td>
<td>x</td>
<td></td>
<td>x</td>
</tr>
<tr>
<td>Daniel K. Burns</td>
<td>Zinfandel Pharmaceuticals Takeda</td>
<td>Full time employee Alliance with Zinfandel Pharmaceuticals</td>
<td>x</td>
<td>x</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gerald Cagle</td>
<td>Cognoptix</td>
<td>Employee</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anne Margrette Cameron</td>
<td>Cognoptix</td>
<td>Consultant</td>
<td>x</td>
<td>x</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pete Castelluccio</td>
<td>Eli Lilly and Company</td>
<td>Independent contractor</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Marco Cecchi</td>
<td>Neuronetrix</td>
<td>Employee</td>
<td>x</td>
<td>x</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Name</td>
<td>Company/Position</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>-----------------------------</td>
<td>--------------------------------------</td>
<td>-----</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>William Cho</td>
<td>Genentech/Roche, Employee</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ping-Chun Chiao</td>
<td>Biogen Idec, Employee</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sophie Claudel</td>
<td>Sanofi, Employee</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Valérie Corp dit Gentil</td>
<td>Sanofi, Employee</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gerald Crans</td>
<td>Elian Pharmaceuticals LLC, Employee</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Donna Crenshaw</td>
<td>Zinfindel Pharmaceuticals, Consultant</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jeffrey Cummings</td>
<td>Genentech, ADAMAS, Anavex, Avanir, Baxter, Bristol-Myers Squibb, Eisai, EnVivo, Genentech, GlaxoSmithKline, Eli Lilly, Lundbeck, Merck, Novartis, Otsuka Pfizer, Prana, QPR Pharma, Resverlogix, Roche, Sosexa, Suven, Takeda, Toyoma, Genentech, ADAMAS, Prana, Soneza, MedAvante, Neurotix, Neurokos, Neuropsychiatric Inventory, Consultant</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stephen Cunnane</td>
<td>Accora, Consultant</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Michael Devous</td>
<td>Avid Radiopharmaceuticals, Inc, Employee</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P. Murali Doraswamy</td>
<td>Avid/Lilly, Grants/Advisor, Genentech, ADAMAS, Prana, Soneza, MedAvante, Neurotix, Neurokos, Advisor, stock shareholder, Consultant</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Julien Dumurgier</td>
<td>Novartis, Travel expenses</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Noel Ellison</td>
<td>Eisai, Roche, Janssen, Independent contractor</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Larry Ereshefsky</td>
<td>Parexel, As a global CRO we have conducted clinical trials for most Pharma across an array of compounds for neurodegenerative disorders, including Alzheimer’s Disease. Additionally, our early phase units (Los Angeles and Baltimore), wholly owned by Parexel, have conducted more than 10 studies over the past two years in Neuromuscular Disorder indications supported by various sponsors including large and small pharma, Michael J Fox Foundation, and NIH.</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Claire Evans</td>
<td>Ichor Medical Systems, Employee</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Christine Fauveau</td>
<td>Sanofi, Employee</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Milan Fiala</td>
<td>Smartfish, Oslo, Norway, Honorarium recipient</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Denis Fortier</td>
<td>Medical Care Corporation, Employee</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Michel Friesenhahn</td>
<td>Genentech, Employee</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Shoozo Furumoto</td>
<td>GE Healthcare, Grants/Research support recipient, Consultant</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Joanne Gale</td>
<td>CogState, Employee</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Serge Gauthier</td>
<td>Eli Lilly and company, Speaker at international conferences</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Michelle Gee</td>
<td>Eisai Limited, Full-time employee</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Katherine Gray</td>
<td>Ixico Ltd., Employee</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Keith Gregg</td>
<td>Janssen AI, Employee, stock shareholder</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kennan Gu</td>
<td>Eisai, Employee</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Volkmar Guenzler</td>
<td>Janssen Alzheimer Immunotherapy, Employee</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baoguang Han</td>
<td>Eli Lilly, Employee and company, Employee</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kristin Hannesdottir</td>
<td>AstraZeneca, Employee</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jutta Hänninen</td>
<td>Orion Corporation, Employee</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Junko Hara</td>
<td>Medical Care Corporation, Employee, Board Member, Stock Shareholder</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>John Harrison</td>
<td>Bracket, Employee, Independent contractor, Consultant</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Samuel T. Henderson</td>
<td>Accora, Employee</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Suzanne Hendrix</td>
<td>Pentara Corporation, Independent contractor</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Karl Herholz</td>
<td>AVID Radiopharmaceuticals, GE Healthcare, Research Grant, Consultant</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Derek Hill</td>
<td>Ixico, Employee and board member, Employee and shareholder</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Akira Hisaka</td>
<td>Takeda Pharmaceuticals, Lab donation (supported by 8 companies)</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Carole Ho</td>
<td>Roche, Stock shareholder</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Name</td>
<td>Affiliation</td>
<td>Relationship</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>-------------------------------</td>
<td>--------------------------------------------</td>
<td>-------------------------------------</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vicky Hoffmann</td>
<td>Eli Lilly and Company</td>
<td>Employee and stock shareholder</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>David Holtzman</td>
<td>C2N Diagnostics</td>
<td>Co-founder and member of the scientific advisory board. C2N Diagnostics has licensed technology from Washington University that will be discussed. This technology is not yet in humans</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Judith Jaeger</td>
<td>CogState</td>
<td>Employee</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>William Jagust</td>
<td>Synarc</td>
<td>Consultant</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jan Johansson</td>
<td>AlphaBeta AB</td>
<td>Founder. Research support.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Abhinay Joshi</td>
<td>Avid Radiopharmaceuticals, Inc</td>
<td>Employee</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yokozuka Kazutoshi</td>
<td>Bell Medical Solutions Inc.</td>
<td>Employee of Bell Medical Solutions Inc which contracted a part of this research from University of Tokyo Hospital</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gene Kinney</td>
<td>Elan Pharmaceuticals</td>
<td>Previous employee and current shareholder</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Charles Kerbage</td>
<td>Cognoptix</td>
<td>Employee</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patrick Kessler</td>
<td>Elian Pharmaceuticals LLC</td>
<td>Employee and Stock Shareholder</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nzeera Ketter</td>
<td>Janssen Alzheimer Immunotherapy</td>
<td>Employee</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stephane Kireksetti</td>
<td>Sanofi</td>
<td>Employee</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hartmut Kolb</td>
<td>Avid Radiopharmaceuticals</td>
<td>Employee</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jeffrey Kordower</td>
<td>Ceregene Inc</td>
<td>Scientific advisor</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yukitsuka Kudo</td>
<td>GE Healthcare Clino</td>
<td>Grants/research support recipient Board member, stock shareholder (excl. mutual funds)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Matthias Kurth</td>
<td>Elian Pharmaceuticals LLC</td>
<td>Employee</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Robert Y K Lai</td>
<td>Eisai</td>
<td>Employee</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jessica Langbaum</td>
<td>National Institute on Aging</td>
<td>1RF1AG041705-01A</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>David Li</td>
<td>Pfizer</td>
<td>Employee</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Enchi Liu</td>
<td>Janssen Alzheimer Immunotherapy</td>
<td>Employee</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hong Liu-Seifert</td>
<td>Eli Lilly and Co.</td>
<td>Employee</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kasia Lobello</td>
<td>Pfizer</td>
<td>Employee</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Veronika Logovinsky</td>
<td>Eisai Inc.</td>
<td>Employee</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ming Lu</td>
<td>Avid Radiopharmaceuticals, Inc</td>
<td>Employee</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prisca Lucas</td>
<td>Pfizer, Inc.</td>
<td>Employee</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ana Lukic</td>
<td>ADMdx</td>
<td>Employee</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Michael Lutz</td>
<td>Zinfandel Pharmaceuticals</td>
<td>Consultant</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Constantine Lyketsos</td>
<td>NIMH, NIA, Associated Jewish Federa-thon of Baltimore, Weinberg Foundation, Forest, Glaxo-Smith-Kline, Eisai, Pfizer, Astra-Zeneca, Lilly, Orch-orth McNeil, Bristol-Myers, Novartis, National Football League, Elan, Functional Neuromodulation Inc., Janssen, Astra-Zeneca, Glaxo-Smith Kline, Eisai, Novartis, Forest, Supemus, Adlyfe, Takeda, Wyeth, Lundbeck, Merz, Lilly, Pfizer, Genentech, Elan, NFI, Players Association, NFL Benefits Office, Avanir, Zinfandel, BMS, Pfizer, Forest, Glaxo-Smith Kline, Health Monitor</td>
<td>Grant support (Research or CME), Consultant Advisor, Honorarium or travel support</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Richard Margolin</td>
<td>Janssen Alzheimer Immunotherapy R&amp;D LLC</td>
<td>Employee</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Renata Martinicova</td>
<td>Sanofi</td>
<td>Employee</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Paul Manoff</td>
<td>CogState</td>
<td>Full-time employee</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dawn Matthews</td>
<td>ADM Diagnostics LLC</td>
<td>CEO, stockholder, employee</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kate McLeish</td>
<td>IXICO</td>
<td>Employee</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Agnes Menut</td>
<td>Sanofi</td>
<td>Employee</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mark Mintun</td>
<td>Avid Radiopharmaceuticals, Inc</td>
<td>Employee</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Richard Mohs</td>
<td>Eli Lilly and Co.</td>
<td>Full time employee and stockholder</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kristen Morris</td>
<td>Elian Pharmaceuticals</td>
<td>Employee</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dennis Nilan</td>
<td>Cognoptix</td>
<td>Employee</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nobuyuki Okamura</td>
<td>GE Healthcare Clino</td>
<td>Grants/research support recipient Consultant, stock shareholder (excl. mutual funds)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jeffrey Ostrove</td>
<td>Ceregene, Inc</td>
<td>Employee, Stockholder</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Claire Paquet</td>
<td>Genentech</td>
<td>Employee</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Robert Paul</td>
<td>Genentech</td>
<td>Employee</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pedro Pesini</td>
<td>Aradon Biotech Ltd.</td>
<td>Employee</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Name</td>
<td>Role and/or Company</td>
<td>Relationship with Company</td>
<td>Notes</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>-----------------------------</td>
<td>----------------------------------------------</td>
<td>------------------------------------</td>
<td>-------</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ron Petersen</td>
<td>Chair Data Monitoring Committee</td>
<td>Pfizer, Inc., Janssen AI GE Healthcare</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Steven Potkin</td>
<td>Consultant</td>
<td>Ceregene</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anton Porsteinsson</td>
<td>Grant/Research Support, Consultant</td>
<td>Elan, Janssen AIP, Avanir, Baxter BMS, EnVivo, Genentech/Roche, Merck, Pfizer, Toyma, Quintiles, Functional, Neuromodulation Forrest</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Derk Purcell</td>
<td>Consultant</td>
<td>Janssen Alzheimer's Immunotherapy</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Michael Ropacki</td>
<td>Employee</td>
<td>Janssen R&amp;D</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Allen D. Roses</td>
<td>CEO and President, a NC S-Corporation with 11 employees, Holder of Intellectual Property Rights</td>
<td>Zinfandel Pharmaceuticals</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Juha Rouru</td>
<td>Employee</td>
<td>Orion Pharmaceuticals</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Daniel Rueckert</td>
<td>Founder, Shareholder, Consultant</td>
<td>IXICO</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Carl Sadowsky</td>
<td>Advisory Board and Speakers' bureau</td>
<td>Novartis, Lilly, Forest, Accera, Cognos, PamLab</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Manuel Sarasa</td>
<td>Employee and CSO</td>
<td>Aracon Biotech Ltd.</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Andrew Satlin</td>
<td>Full-time employee</td>
<td>Eisai, Inc.</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ann M. Saunders</td>
<td>Wife of Allen Roses CEO and consultant</td>
<td>Zinfandel Pharmaceuticals</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adrian Schembri</td>
<td>Employee</td>
<td>CogState, Inc</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mark Schmidt</td>
<td>Full time employee of Janssen Pharmaceutica and scientific advisor to Janssen Alzheimer Immunotherapy</td>
<td>Janssen Pharmaceutica, NV</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lon Schneider</td>
<td>Consulting and DMC</td>
<td>Toyama Fujifilm, En Vivo Novartis, AC Immune, Abbvie Baxter, Biogen, Idec, Piramal Targacept, Tau Rx, Eli Lilly, Johnson and Johnson, Takeda and Zinfandel, Allon, Roche, AstraZeneca, AC Immune Merck</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adam Schwarz</td>
<td>Employee and shareholder</td>
<td>Eli Lilly and Co.</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>William Shankle</td>
<td>Employee, Board Member, Stock Shareholder</td>
<td>Medical Care Corporation</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sergey Shcherbinin</td>
<td>Employee</td>
<td>Eli Lilly and Company</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jeffrey Sevigny</td>
<td>Employee</td>
<td>Biogen Idec</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eric Siemers</td>
<td>Employee and Shareholder</td>
<td>Eli Lilly and Company</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Joao Silfert</td>
<td>Former employee and stock shareholder</td>
<td>Ceregene Inc.</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Daniel Skovronsky</td>
<td>Employee</td>
<td>Avid Radiopharmaceuticals Eli Lilly and Company</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adina Soaita</td>
<td>Employee</td>
<td>Cogstate</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jeanne Stemmelin</td>
<td>Employee</td>
<td>Sanoﬁ</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Robert Stern</td>
<td>Consultant, Past research support for site clinical trial</td>
<td>Athena Diagnostics, Janssen Alzheimer’s Immunotherapy, Janssen Alzheimer Immunotherapy R&amp;D</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stephen Strother</td>
<td>Part-owner and part-time employee of ADM Diagnostics where this modeling work was performed.</td>
<td>ADM Diagnostics</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Scott Styren</td>
<td>Employee</td>
<td>Pfizer</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>David Sultzer</td>
<td>Research Support, consultant Research Support</td>
<td>Eli Lilly and Co., Otsuka</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Karen Sundell</td>
<td>Employee and minor stockholder</td>
<td>Eli Lilly and Co.</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chad Swanson</td>
<td>Full-time employee</td>
<td>Eisai, Inc.</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pierre Tariot</td>
<td>Grant/Research support recipient Consultant</td>
<td>Genentech, Lilly/Abbott, NIH/NIA, Aonymous Foundation, State of Arizona AC-Immune</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Michael Valenzuela</td>
<td>Research support and speaker’s honoraria from The Brain Department Pty Ltd for work unrelated to this report. In-kind research support from BrainTrain for a study unrelated to this report. Research funding and speaker’s honoraria from Pfizer Neuroscience Australia for work unrelated to this report.</td>
<td>Brain Department Pty Ltd</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
The following have no relevant financial relationships to disclose:


The CME staff, meeting planners, planning committee and CME committee reviewers do not have any relevant financial relationships to disclose.

This educational activity may contain discussion of unlabeled and/or investigational uses of agents that are not approved by the FDA. Please consult the prescribing information for each product. The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views of the University of California, San Diego.
Clinical Trials on Alzheimer’s Disease (CTAD) would like to thank the following companies for their ongoing support helping CTAD meet its mission and goals.

**Sponsors**

- Abbvie
- Eisai
- GE Healthcare
- Janssen
- Pfizer
- Lilly
- Nutricia
Clinical Trials on Alzheimer's Disease

www.ctad-alzheimer.com

November 20-22, 2014
Philadelphia